HGVSc	SYMBOL	Pos_chr	Pos_start	Allele	aliquot_id	Consequence	clinvar_clnsig	clinvar_golden_stars	clinvar_rs	clinvar_trait	ClinVar	ClinVar_ALLELEID	ClinVar_CLNDN	ClinVar_CLNDNINCL	ClinVar_CLNDISDB	ClinVar_CLNDISDBINCL	ClinVar_CLNHGVS	ClinVar_CLNREVSTAT	ClinVar_CLNSIG	ClinVar_CLNSIGCONF	ClinVar_CLNSIGINCL	ClinVar_CLNVC	ClinVar_CLNVCSO	ClinVar_CLNVI	ClinVar_DBVARID	ClinVar_GENEINFO	ClinVar_MC	ClinVar_ORIGIN	ClinVar_RS	ClinVar_SSR	ClinVar_CLNSUBA	ClinVar_CLNSIGA	ClinVar_CLNDATEA	ClinVar_CLNDATESUBA	ClinVar_CLNREVSTATA	ClinVar_CLNORA	ClinVar_CLNSCVA	ClinVar_CLNDNA	ClinVar_CLNCOMA	TCGA_cases
NM_014967.4:c.*3+1G>A	FAN1	chr15	31229463	A	2791f44f-ce4c-4893-b074-9eebd761dbaf;b89d250f-5d92-414e-9859-5611ade30949;65e850b3-9f62-4a4f-94ce-b924103d54ff;6ee9f695-6ebc-49e9-ae59-561c8b6bbeea;83958ee7-16aa-4a09-a5d2-7104dc1d454a;c3c2704a-4d2a-4ee6-b69f-435d01d62809;17a5f8b5-fa9a-41c5-bbd8-1c443e8daa85;bac2cf85-be6d-4d68-91bf-83daab5ea3a6;74ff4e7e-9b8b-40cb-8d05-bf5c2ac2cdc0	splice_donor_variant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TCGA_UCEC_016;TCGA_UCEC_043;TCGA_UCEC_136;TCGA_UCEC_207;TCGA_UCEC_277;TCGA_UCEC_343;TCGA_UCEC_361;TCGA_UCEC_426;TCGA_UCEC_504
NM_002528.6:c.268C>T	NTHL1	chr16	2096239	A	8587d094-3f35-44bf-9825-a071044b7b40;49f475c3-3f95-45c6-8446-17acfc7f21c7	stop_gained	5	0	rs150766139	Familial adenomatous polyposis 3	192319	190112	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C4225157,OMIM:616415,Orphanet:ORPHA454840|MedGen:CN517202	-	NC_000016.9:g.2096239G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:602656.0001	-	NTHL1:4913	SO:0001627|intron_variant	1	150766139	-	OMIM|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Invitae|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|Ambry_Genetics	Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2015-06-01|2017-01-13|2019-01-04|2019-01-08|2018-01-26|2018-10-17	2016-08-11|2018-09-19|2019-01-29|2019-03-28|2018-04-23|2020-02-26	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline|germline	SCV000223893|SCV000705556|SCV000779405|SCV000957470|SCV000992218|SCV001177246	Familial_adenomatous_polyposis_3|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	||This_pathogenic_variant_is_denoted_NTHL1_c.268C>T_at_the_cDNA_level_and_p.Gln90Ter_(Q90X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glycine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_several_individuals_with_colorectal_cancer_and/or_adenomas_(Dallosso_2008,_Rivera_2015,_Timofeeva_2015,_Weren_2015)._Weren_et_al._(2015)_identified_NTHL1_Gln90Ter_in_the_homozygous_state_in_7_individuals_from_three_families_with_a_history_of_multiple_colorectal_adenomas_and/or_colorectal_cancer._Additionally,_Rivera_et_al._(2015)_identified_NTHL1_Gln90Ter_in_the_compound_heterozygous_state_with_a_canonical_splice_variant,_confirmed_to_be_in_trans_through_familial_testing,_in_an_individual_with_colon_cancer,_multiple_colorectal_adenomas,_and_other_neoplasms._Lastly,_other_studies_identified_NTHL1_Gln90Ter_in_the_homozygous_or_compound_heterozygous_state_in_several_unrelated_individuals_with_colorectal_adenomas_and_colorectal_cancer_(Chubb_2016,_Belhadj_2017,_Broderick_2017)._Based_on_currently_available_information,_we_consider_NTHL1_Gln90Ter_to_be_pathogenic._Of_note,_NTHL1-Associated_Polyposis_(NAP)_is_a_recessive_condition_associated_with_two_pathogenic_variants_on_opposite_chromosomes_in_NTHL1._Although_this_variant_is_considered_pathogenic,_a_second_pathogenic_variant,_as_would_be_required_for_expression_of_the_recessive_condition_NAP,_was_not_detected_in_this_individual._We_cannot_exclude_the_possibility_that_this_patient_harbors_a_second_disease-causing_NTHL1_pathogenic_variant_that_is_undetectable_by_this_test._NTHL1_has_only_recently_been_described_in_association_with_cancer_predisposition_and_the_risks_are_not_well_understood._Based_on_available_data,_the_presence_of_two_pathogenic_variants_in_NTHL1_is_indicative_of_NTHL1-Associated_Polyposis_(NAP),_an_autosomal_recessive_condition_that_may_confer_an_increased_risk_for_colorectal_cancer_and_polyps._Although_the_development_of_colorectal_cancer_and_attenuated_polyposis_appears_to_be_the_predominant_feature_of_NAP,_multiple_case_reports_have_described_individuals_with_NAP_to_have_developed_multiple_extracolonic_neoplasms,_including_breast,_endometrial,_bladder,_and_skin_cancers_as_well_as_several_benign_findings_(Rivera_2015,_Weren_2015,_Belhadj_2017)._The_National_Comprehensive_Cancer_Network_has_management_guidelines_for_individuals_with_two_pathogenic_variants_in_NTHL1_(NCCN).|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln90*)_in_the_NTHL1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs150766139,_ExAC_0.4%)._This_variant_has_been_observed_as_homozygous,_and_on_the_opposite_chromosome_(in_trans)_from_a_likely_pathogenic_variant,_in_many_individuals_affected_with_multiple_adenomatous_polyps_and_often_colorectal_cancer_(PMID:Â¬â€ 25938944,_27720914,Â¬â€ 26559593)._These_findings_are_consistent_with_autosomal_recessive_inheritance,_and_suggest_that_this_variant_contributes_to_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_192319)._Experimental_studies_have_shown_that_deletion_of_the_N-terminal_92_amino_acids_of_the_NTHL1_protein_results_in_complete_loss_of_its_activity_(PMID:_12144783)._Loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)	TCGA_UCEC_041;TCGA_UCEC_045
NM_058216.2:c.397C>T	RAD51C	chr17	56772543	T	44404450-cc28-45de-b297-52377f8b88ee	stop_gained	5&5	1&1	rs387907159	Fanconi anemia, complementation group O&Hereditary cancer-predisposing syndrome	31556	40236	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56772543C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Counsyl:71036|OMIM_Allelic_Variant:602774.0005	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	387907159	-	OMIM|Counsyl|Invitae|Counsyl|Ambry_Genetics|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America	risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-04-26|2016-06-08|2018-11-02|2016-06-08|2019-01-22|2018-02-20|2019-06-03	2019-08-21|2016-11-23|2019-03-28|2016-11-23|2020-02-26|2019-01-29|2019-09-24	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|unknown|germline|germline|germline	SCV000045555|SCV000489818|SCV000260887|SCV000489817|SCV000274438|SCV000567793|SCV000699808	Breast-ovarian_cancer,_familial_3|Breast-ovarian_cancer,_familial_3|Fanconi_anemia,_complementation_group_O|Fanconi_anemia,_complementation_group_O|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome	||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln133*)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs387907159,_ExAC_0.002%)._This_variant_has_been_reported_in_families_with_breast_and/or_ovarian_cancer_(PMID:_21990120,_22538716)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_31556)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_pathogenic_variant_is_denoted_RAD51C_c.397C>T_at_the_cDNA_level_and_p.Gln133Ter_(Q133X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_individuals_with_breast_and/or_ovarian_cancer_(Loveday_2012,_Thompson_2012)_and_is_considered_pathogenic.|Variant_summary:_RAD51C_c.397C>T_(p.Gln133X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory._The_variant_allele_was_found_at_a_frequency_of_4e-06_in_250888_control_chromosomes_(gnomAD)._c.397C>T_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Hu_2018,_Loveday_2012,_Thompson_2011)_including_a_family_in_which_an_unaffected_individual_carried_the_variant_suggesting_reduced_penetrance_(Thompson_2011)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Four_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.	TCGA_UCEC_053
NM_000179.2:c.1772del	MSH6	chr2	48026890	-	710120c8-6c68-4cba-99d3-5aea8c69f468	frameshift_variant	-	-	-	-	185350	182081	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000002.11:g.48026894del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	MSH6:2956	SO:0001589|frameshift_variant	1	786202108	-	Ambry_Genetics	Pathogenic	2018-04-23	2020-02-26	_single_submitter	germline	SCV000215432	Hereditary_cancer-predisposing_syndrome	_nonsense)	TCGA_UCEC_068
NM_000179.2:c.3959_3962del	MSH6	chr2	48033745	-	b91ef015-ee09-4caa-9177-519a83c24230	frameshift_variant	-	-	-	-	89488	94962	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48033748_48033751del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	_Inc:MSH6-A19|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2830312	-	MSH6:2956	SO:0001589|frameshift_variant	1	267608120	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Ambry_Genetics|Color|Counsyl|Center_for_Human_Genetics,_Inc|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2015-06-08|2016-07-05|2018-03-09|2019-05-05|2016-09-06|2016-09-21|2016-11-01|2018-10-16|2016-07-25|2019-01-05	2013-12-18|2017-04-19|2018-01-25|2019-03-21|2020-02-26|2017-10-26|2016-11-23|2017-12-20|2019-01-29|2018-08-31|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline	SCV000108171|SCV000592665|SCV000695902|SCV000966976|SCV000273693|SCV000685467|SCV000489342|SCV000781796|SCV000566279|SCV000601592|SCV000551155	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon||Variant_summary:_The_MSH6_c.3959_3962delCAAG_(p.Ala1320Glufs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MSH6_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._If_this_variant_escapes_NMD,_it_is_expected_to_truncate_P-loop_containing_nucleoside_triphosphate_hydrolase._Other_similar_truncations_variants_in_this_gene_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Ala1320fs)._This_variant_is_absent_in_122768_control_chromosomes._This_variant_has_been_reported_in_literature_as_a_pathogenic_variant_found_in_several_patients_with_Lynch_syndrome_related_cancers_(Goodfellow_2003,_Raskin_2015)._It_is_regarded_as_a_founder_mutation_in_Ashkenazi_Jews._Multiple_clinical_labs/reputable_databases_have_classified_it_as_pathogenic._Taken_together,_this_variant_is_classified_as_Pathogenic.|The_p.Ala1320fs_variant_in_MSH6_has_been_reported_in_at_least_15_individuals_wit_h_Lynch_Syndrome-associated_cancers_(Goodfellow_2003,_Hampel_2005,_Raskin_2011,_Goldberg_2014,_Yurgelun_2015)_and_is_believed_to_be_an_Ashkenazi_Jewish_founder_variant_(Raskin_2011)._It_has_also_been_reported_in_the_compound_heterozygous_st_ate_in_one_family_with_constitutional_mismatch_repair_deficiency_syndrome,_where_the_variant_was_identified_in_3_siblings_who_also_had_a_second_pathogenic_varia_nt_in_MSH6_(Bakry_2014)._This_variant_has_been_identified_in_3/9796_Ashkenazi_Je_wish_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broad_institute.org:_dbSNP_rs267608120)._This_variant_is_predicted_to_cause_a_frameshi_ft,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_1320_an_d_leads_to_a_premature_termination_codon_6_amino_acids_downstream._Although_nons_ense_mediated_decay_is_generally_less_likely_to_occur_at_this_position_(within_t_he_terminal_50_bases_of_the_penultimate_exon),_tumors_from_two_patients_with_thi_s_variant_have_been_found_to_have_loss_of_MSH6_protein_expression_(Raskin_2011,_Bakry_2014)._Heterozygous_loss_of_function_of_the_MSH6_gene_is_an_established_di_sease_mechanism_in_individuals_with_Lynch_syndrome._Additionally,_this_variant_h_as_been_classified_as_pathogenic_on_Sept._5,_2013_by_the_ClinGen-approved_InSiGH_T_expert_panel_(SCV000108171.2)._In_summary,_this_variant_meets_criteria_to_be_c_lassified_as_pathogenic_for_Lynch_Syndrome_in_an_autosomal_dominant_manner_based_upon_presence_in_multiple_affected_individuals,_very_low_frequency_in_the_gener_al_population,_functional_evidence._ACMG/AMP_Criteria_applied_(Richards_2015):_P_S4,_PS3,_PM2,_PM4.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_deletion_of_four_nucleotides_in_MSH6_is_denoted_c.3959_3962delCAAG_at_the_cDNA_level_and_p.Ala1320GlufsX6_(A1320EfsX6)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AAAG[delCAAG]AGAA._The_deletion_causes_a_frameshift,_which_changes_an_Alanine_to_a_Glutamic_Acid_at_codon_1320,_and_creates_a_premature_stop_codon_at_position_6_of_the_new_reading_frame,_resulting_in_the_last_41_correct_amino_acids_being_replaced_by_5_incorrect_ones._This_frameshift_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._MSH6_c.3959_3962delCAAG_has_been_observed_in_several_individuals_with_Lynch_syndrome,_has_been_reported_in_the_compound_heterozygous_state_in_one_family_with_three_individuals_with_Constitutional_Mismatch_Repair_Deficiency_(CMMR-D),_and_is_published_as_an_Ashkenazi_Jewish_founder_variant_(Goodfellow_2003,_Raskin_2011,_Baris_2016)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_MSH6_gene_(p.Ala1320Glufs*6)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_41_amino_acids_of_the_MSH6_protein._This_variant_is_present_in_population_databases_(rs267608119,_ExAC_0.002%)._This_variant_has_been_reported_in_numerous_individuals_and_families_affected_with_Lynch_syndrome,_and_is_considered_a_founder_mutation_in_the_Ashkenazi_Jewish_population_(PMID:_12732731,_21155762,_20028993,_24440087,_23990280,_25430799,_20007843,_26544533)._This_variant_is_also_known_as_3956_3959delAAGC_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89488)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.	TCGA_UCEC_099
NM_000179.2:c.843_844insAC	MSH6	chr2	48025965	AC	a2f9968e-22a1-4771-a267-92d298c12f4b	frameshift_variant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TCGA_UCEC_132
NM_014967.4:c.1811+1G>A	FAN1	chr15	31206295	A	d3faa643-43d6-4d34-8ccd-866afe0e4666	splice_donor_variant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TCGA_UCEC_147
NM_000546.5:c.376-2dup	TP53	chr17	7578555	T	ed777919-93d9-483a-a5e8-364f89f19353	splice_acceptor_variant	-	-	-	-	185593	185393	Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|not_specified|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.7578556dup	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	-	-	Duplication	SO:1000035	-	-	TP53:7157	SO:0001623|5_prime_UTR_variant	1	751253294	-	Ambry_Genetics|Color|GeneKor_MSA|Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance	2019-08-29|2018-03-16|2018-08-01|2018-12-04|2016-08-29|2019-02-05	2020-02-26|2018-11-06|2018-08-08|2019-03-28|2017-11-28|2020-03-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000215739|SCV000691592|SCV000822206|SCV000285192|SCV000293780|SCV000602270	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|not_specified|not_provided	Insufficient_or_conflicting_evidence|||This_sequence_change_falls_in_intron_4_of_the_TP53_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_TP53_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_TP53-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185593)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|This_variant_is_denoted_TP53_c.376-2dupA_or_IVS4-2dupA_and_consists_of_a_duplication_of_one_nucleotide_at_the_-2_position_in_intron_4_of_the_T53_gene._The_normal_sequence,_with_the_base_that_is_duplicated_in_braces,_is_ctac{a}gTAC,_where_the_capital_letters_are_exonic_and_lowercase_are_intronic._The_adenine_(A)_nucleotide_that_is_duplicated_is_conserved_across_species_and_is_part_of_the_canonical_splice_acceptor_site._Multiple_in_silico_models_predict_this_variant_to_cause_a_reduction_in_use_of_this_natural_splice_acceptor_site,_and_to_possibly_cause_abnormal_gene_splicing._However,_in_the_absence_of_RNA_or_functional_studies,_the_actual_effect_of_this_variant_is_unknown._TP53_c.376-2dupA_was_not_observed_in_approximately_6,500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_indicating_it_is_not_a_common_benign_variant_in_these_populations._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature_as_pathogenic_or_benign._Based_on_currently_available_information,_we_consider_TP53_c.376-2dupA_to_be_a_variant_of_uncertain_significance.|	TCGA_UCEC_158
NM_007294.3:c.3748G>T	BRCA1	chr17	41243800	A	0fbdf4bd-75c6-48dc-b23e-8d056c466056	stop_gained	5&5&5&5	3&1&1&1	rs28897686	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&not provided&Hereditary cancer-predisposing syndrome	17672	32711	_familial_1|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.41243800C>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Queen's_University:722481|OMIM_Allelic_Variant:113705.0013	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	28897686	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Baylor_Genetics|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1994-12-01|2012-04-05|2002-05-29|2015-11-20|2016-09-08|2015-10-02|2015-06-17|0000-00-00|2014-10-08|2015-09-21|2018-12-28|2014-01-31|2017-04-20|2012-11-19|2016-05-23|2018-12-31|2019-07-06|2019-02-11|2016-12-19|2017-02-23|2017-01-11	2018-03-12|2013-12-30|2014-03-28|2016-03-03|2016-09-13|2016-10-28|2017-06-22|2018-04-04|2018-04-17|2018-04-09|2019-03-28|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2019-01-29|2020-03-06|2020-02-26|2017-10-26|2017-02-23|2017-06-30	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000039529|SCV000109357|SCV000144858|SCV000266030|SCV000300004|SCV000325737|SCV000677650|SCV000733619|SCV000743401|SCV000744626|SCV000076324|SCV000587340|SCV000588048|SCV000591470|SCV000699068|SCV000108671|SCV000296296|SCV000186866|SCV000683129|SCV000540952|SCV000602708	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|not_specified	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu1250*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs28897686,_ExAC_0.003%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_7894491,_12497638,_24504028,_24728189)._This_variant_is_also_known_as_3867G>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_17672)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_summary:_The_BRCA1_c.3748G>T_(p.Glu1250X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.3904G>T/p.Glu1302X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_2/121388_control_chromosomes_at_a_frequency_of_0.0000165,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA1_variant_(0.0010005)._This_variant_has_been_reported_in_multiple_affected_individuals_and_functional_study_showed_variant_with_~10%_of_relative_HDR_activity_in_comparison_to_WT_BRCA1_(Lu_2015)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_pathogenic_variant_is_denoted_BRCA1_c.3748G>T_at_the_cDNA_level_and_p.Glu1250Ter_(E1250X)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA1_3867G>T._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_Glu1250Ter_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Castilla_1994,_Ahmad_2012,_Cunningham_2014,_Weren_2016)_and_is_considered_pathogenic.|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||	TCGA_UCEC_310
NM_000251.2:c.1511-2A>G	MSH2	chr2	47693795	G	b953c4e5-e489-455a-98e8-a635e95c5d81	splice_acceptor_variant	-	-	-	-	90688	96163	Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.47693795A>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1511-2A>G	-	MSH2:4436	SO:0001574|splice_acceptor_variant	1	267607962	-	Mayo_Clinic	Pathogenic|Pathogenic|Pathogenic	2013-09-05|2018-08-06|0000-00-00	2013-12-18|2020-02-26|2017-10-31	_single_submitter|no_assertion_criteria_provided	germline|germline|unknown	SCV000107201|SCV000580440|SCV000691905	Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	Variant_causes_splicing_aberration_causing_frameshift:_full_inactivation_of_variant_allele|Functionally-validated_splicing_mutation:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|	TCGA_UCEC_325
NM_000179.2:c.2565del	MSH6	chr2	48027686	-	2a8cb8fe-b64f-453e-8139-7ede12f3fc51	frameshift_variant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TCGA_UCEC_382
NM_002485.4:c.698_701del	NBN	chr8	90983402	-	df73c2f3-0c35-4aec-82c4-f4ee268636f0	frameshift_variant,splice_region_variant	-	-	-	-	127878	133335	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90983404_90983407del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	OMIM_Allelic_Variant:602667.0002|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2844349	-	NBN:4683	SO:0001589|frameshift_variant	1	587780100	-	_University_of_Chicago|Invitae|GeneReviews|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-04-12|2016-07-26|1998-05-01|2015-03-05|2018-12-18|2017-02-02|2018-08-03|2018-07-23|2018-04-11	2020-02-26|2017-10-26|2016-06-24|2015-09-15|2019-03-28|2017-02-02|2019-04-24|2019-01-29|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000213967|SCV000685816|SCV000027554|SCV000248142|SCV000261243|SCV000494629|SCV000917863|SCV000149713|SCV000889556	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|not_provided|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys233Serfs*5)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780100,_ExAC_0.01%)._This_variant_has_been_observed_inÂ¬â€ individuals_affected_with_Nijmegen_breakage_syndrome_(NBS),_and_breast/ovarian_cancer_(PMID:_9590180,_15474156,_26315354,_26534844)._This_variant_is_also_known_as_698del4_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127878)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_NBN_c.698_701delAACA_(p.Lys233SerfsX5)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_2e-05_in_252006_control_chromosomes_(gnomAD)._The_variant,_c.698_701delAACA,_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_and_Nijmegen_Breakage_Syndrome_(Varon_1998,_Gass_2017,_Ramus_2015,_Li_2015,_Susswein_2016)._These_data_indicate_that_the_variant_may_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_deletion_of_four_nucleotides_in_NBN_is_denoted_c.698_701delAACA_at_the_cDNA_level_and_p.Lys233SerfsX5_(K233SfsX5)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GCCA[delAACA]Ggta,_where_the_capital_letters_are_exonic_and_lowercase_are_intronic._The_deletion_causes_a_frameshift,_changing_a_Lysine_to_a_Serine_at_codon_233,_and_creates_a_premature_stop_codon_at_position_5_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_published_as_NBN_or_NBS1_698del4,_has_been_reported_in_families_with_Nijmegen_Breakage_Syndrome_as_well_as_in_women_with_breast_and_ovarian_cancer_(Varon_1998,_Meyer_2004,_Ramus_2015,_Li_2016,_Gass_2017),_and_is_considered_pathogenic.|	TCGA_UCEC_410
NM_000179.2:c.1135_1139del	MSH6	chr2	48026251	-	115bc657-cc38-4e9a-9196-7e2acab6f548	frameshift_variant	-	-	-	-	89174	94648	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48026252_48026256AGAGA[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1135_1139del	-	MSH6:2956	SO:0001587|nonsense	1	267608077	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Genetic_Services_Laboratory,_University_of_Chicago|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2013-09-05|2015-11-20|2018-12-26|2019-02-23|2015-03-30|2018-01-15|0000-00-00|2016-08-19|2018-12-07	2013-12-18|2016-03-03|2019-04-24|2020-02-26|2017-10-26|2019-01-29|2015-11-19|2017-07-05|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000107835|SCV000266088|SCV000917791|SCV000184650|SCV000685168|SCV000211383|SCV000257205|SCV000595850|SCV000750903	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon||Variant_summary:_MSH6_c.1135_1139delAGAGA_(p.Arg379X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_245726_control_chromosomes_(gnomAD)._c.1135_1139delAGAGA_has_been_reported_in_the_literature_in_individuals_affected_with_Breast_cancer,_Ovarian_cancer,_polyups,_and_cervical_cancer_(Frolova_2017,_Kets_2006,_Shirts_2015,_Susswein_2015)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Six_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification||This_deletion_of_5_nucleotides_is_denoted_MSH6_c.1135_1139delAGAGA_at_the_cDNA_level_and_p.Arg379Ter_(R379X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_GAGA[AGAGA]TGAG._The_deletion_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_1135_1139delAGAGA_has_been_observed_in_at_least_two_individuals_with_a_personal_history_of_endometrial_cancer_and_a_family_history_of_Lynch_syndrome-related_cancers_(Kets_2006,_Frolova_2015)._This_variant_is_considered_pathogenic.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg379*)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs777907133,_ExAC_0.001%)._This_variant_has_beenÂ¬â€ observedÂ¬â€ in_several_individuals_affected_with_colorectal_polyps,_endometrial_cancer,_and_cervical_cancer_(PMID:_26845104,_17117178,_26681312,_25617771),_as_well_as_in_individualsÂ¬â€ undergoing_testing_for_Lynch_syndrome_(PMID:Â¬â€ 28514183)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89174)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.	TCGA_UCEC_414
NM_024675.3:c.599del	PALB2	chr16	23647268	-	24df9085-d785-49d1-8ef4-11d7ee04f677	frameshift_variant	-	-	-	-	141880	151594	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23647271del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	PALB2:79728	SO:0001587|nonsense	1	587782081	-	Ambry_Genetics|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic	2019-02-11|2018-07-17|2017-12-12	2020-02-26|2019-01-29|2018-04-02	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000185449|SCV000293387|SCV000550716	Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_deletion_of_one_nucleotide_in_PALB2_is_denoted_c.599delT_at_the_cDNA_level_and_p.Leu200Ter_(L200X)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_CTTT[delT]AAGT._The_deletion_causes_a_nonsense_variant,_which_changes_a_Leucine_to_a_premature_stop_codon_(TTA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.599delT_has_been_reported_in_individuals_with_breast_and/or_ovarian_cancer_(Tung_2016,_Kotsopoulos_2017)._We_consider_this_variant_to_be_pathogenic.|This_sequence_change_deletes_1_nucleotide_from_exon_4_of_the_PALB2_mRNA_(c.599delT),_causing_a_frameshift_at_codon_200._This_creates_a_premature_translational_stop_signal_(p.Leu200*)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer_and_ovarian_cancer_(PMID:_26976419,_27631815)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.	TCGA_UCEC_430
NM_007294.3:c.68_69del	BRCA1	chr17	41276045	-	257387b0-f3a0-4453-a7d8-ec2855239d4c	frameshift_variant	-	-	-	-	17662	32701	_familial_1|Pancreatic_cancer_4|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:C3280442,OMIM:614320|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41276045_41276046CT[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Breast_Cancer_Information_Core__(BRCA1):185&base_change%3Ddel_AG|Department_of_Pathology_and_Molecular_Medicine,Queen's_University:723501|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:68587|Illumina_Clinical_Services_Laboratory,Illumina:678897|OMIM_Allelic_Variant:113705.0003|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:1981909	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	5	80357914	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Pathway_Genomics|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Counsyl|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Genologica_Medica|Bioinformatics_dept.,Datar_Cancer_Genetics_Limited,_India|Genetic_Services_Laboratory,_University_of_Chicago|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genomic_Research_Center,_Shahid_Beheshti_University_of_Medical_Sciences|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|OMIM|Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Illumina_Clinical_Services_Laboratory,Illumina|Cancer_Genetics_and_Genomics_Laboratory,British_Columbia_Cancer_Agency|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|GeneReviews|GeneDx|Baylor_Genetics|GeneKor_MSA|Ambry_Genetics|Color|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|risk_factor|pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|pathologic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2008-10-01|2013-11-14|2002-05-29|2014-07-24|2014-11-03|2014-05-30|2015-11-20|2016-04-22|2015-10-02|2015-07-01|2017-01-01|2017-07-14|2016-12-02|0000-00-00|2017-12-03|2017-05-25|2019-01-22|2008-10-01|2012-07-13|2019-01-04|2016-01-19|2016-06-14|2017-04-18|2014-01-31|2017-04-20|0000-00-00|2017-08-10|2018-07-02|2013-09-26|2014-10-06|2017-02-23|2018-08-01|2019-02-13|2015-01-12|2018-05-23|2016-05-09|2018-11-19|2019-02-25|2016-11-29|2016-07-11|2016-06-22|2017-07-31|2018-12-01|2018-09-13	2018-08-17|2015-12-29|2014-03-28|2014-08-08|2016-04-21|2015-03-11|2016-03-03|2016-06-09|2016-10-28|2017-04-17|2017-03-15|2017-07-19|2017-07-05|2018-04-04|2017-12-03|2018-06-14|2019-08-02|2018-08-17|0000-00-00|2019-03-28|2019-03-21|2016-10-18|2017-08-04|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2018-08-20|2013-04-30|2015-02-20|2017-02-23|2018-08-08|2020-02-26|2016-07-05|2018-05-23|2018-09-19|2019-01-29|2020-03-06|2018-03-09|2018-01-29|2018-07-18|2018-04-30|2019-02-22|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|inherited|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|not_provided|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline	SCV000039518|SCV000053880|SCV000144169|SCV000189887|SCV000195875|SCV000220360|SCV000266036|SCV000282348|SCV000326390|SCV000564332|SCV000577914|SCV000583605|SCV000593688|SCV000733684|SCV000746289|SCV000839891|SCV000993552|SCV000053475|SCV000043189|SCV000077108|SCV000271311|SCV000403078|SCV000586860|SCV000587006|SCV000588022|SCV000591232|SCV000699291|SCV000839317|SCV000086950|SCV000108687|SCV000540943|SCV000693502|SCV000186370|SCV000292122|SCV000803154|SCV000227400|SCV000278833|SCV000296272|SCV000778781|SCV000806982|SCV000863618|SCV000901065|SCV000923765|SCV000602669	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Pancreatic_cancer_4|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|not_provided|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms|not_specified	|||||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||||The_c.68_69del_(p.Glu23Valfs*17)_variant_in_the_BRCA1_gene_has_been_detected_multiple_patients_with_breast_cancer_and/or_ovarian_cancer_[PMID_14576434,_26718727,_21503673,_22430266,_23633455,_22752604,_referred_as_c.185delAG_in_some_publications]._This_variant_is_a_founder_mutation_in_Ashkenazi_Jews_with_a_frequency_of_about_1%_[PMID_14576434]._The_variant_has_also_been_detected_in_patients_with_prostate_[PMID_22516946]_and_pancreatic_cancer_[PMID_20711688,_24737347,_23658460,_26440929]._This_one_bp_deletion_in_exon_2_results_in_a_frameshift_and_the_creation_of_a_premature_stop_codon._Functional_in_vitro_assays_showed_that_this_variant_was_deleterious_[PMID_23867111]._This_variant_has_been_reported_in_31_individuals_from_the_ExAC_database_(http://exac.broadinstitute.org/variant/22-29091226-TA-T)._This_variant_is_thus_classified_as_pathogenic|||Converted_during_submission_to_Pathogenic.|This_sequence_change_deletes_two_nucleotides_from_exon_2_of_the_BRCA1_mRNA_(c.68_69delAG),_causing_a_frameshift_at_codon_23._This_creates_a_premature_translational_stop_signal_(p.Glu23Valfs*17)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_pathogenic_variant_is_a_known_common_cause_of_breast_and_ovarian_cancer_in_the_Ashkenazi_Jewish_population_(PMID:_9042909,_22430266),_although_it_has_been_observed_in_individuals_from_other_ethnicities_(PMID:_8651293,_8571953,_9921907)._This_variant_has_also_been_reported_in_individuals_affected_with_pancreatic_cancer_(PMID:_15994883,_22430266,_23658460,_24737347)._It_is_also_known_as_185delAG_or_187delAG_in_the_literature._This_variant_has_been_associated_with_a_64%_to_83%_risk_of_breast_cancer_by_age_70,_and_a_14%_to_58%_risk_of_ovarian_cancer_by_age_70_(PMID:_15994883,_22430266)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Glu23ValfsX17_variant_in_BRCA1_has_been_reported_in_numerous_individuals_w_ith_hereditary_breast_and_ovarian_cancer_(HBOC)_and_is_a_known_pathogenic_Ashken_azi_Jewish_founder_variant_(Struewing_1997,_Abeliovich_2013)._It_has_also_been_i_dentified_in_38/10150_Ashkenazi_Jewish_and_11/126308_European_chromosomes_by_gno_mAD_(http://gnomad.broadinstitute.org)._Please_note_that_this_frequency_is_low_e_nough_to_be_consistent_with_the_frequency_of_HBOC_in_the_general_population._Thi_s_frameshift_variant_is_predicted_to_alter_the_protein?s_amino_acid_sequence_beg_inning_at_position_23_and_lead_to_a_premature_termination_codon_17_amino_acids_d_ownstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_pr_otein._Heterozygous_loss_of_function_of_the_BRCA1_gene_is_an_established_disease_mechanism_in_individuals_with_HBOC._Additionally,_this_variant_was_classified_a_s_Pathogenic_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(Clin_Var_SCV000282348.1)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_the_predicted_im_pact_to_the_protein_and_presence_in_multiple_affected_individuals._ACMG/AMP_Crit_eria_applied:_PVS1,_PS4_strong.|The_c.68_69delAG_(p.Glu23ValfsTer17)_variant,_also_commonly_known_as_185delAG,_is_a_frameshift_variant_that_is_very_well_described_in_the_literature_as_one_of_the_most_frequent_variants_found_in_breast_cancer_(Shattuck-Eidens_et_al._1995:_Offit_et_al._1996)._It_was_first_identified_in_a_study_by_Simard_et_al._(1994)_in_index_cases_from_four_unrelated_Canadian_families_with_hereditary_breast_and_ovarian_cancer_(HBOC)._Wang_et_al._(2012)_conducted_a_meta-analysis_of_over_29_studies_published_between_2000_and_2010_and_determined_the_overall_frequency_of_the_p.Glu23ValfsTer17_variant_in_2128_breast_cancer_cases_to_be_0.072._The_variant_is_one_of_three_known_common_founder_germline_variants_primarily_found_in_individuals_of_Ashkenazi_Jewish_heritage_(Struewing_et_al._1997:_Abeliovich_et_al._1997:_Laitman_et_al._2013)_and_has_been_detected_in_20%_of_Ashkenazi_Jewish_women_diagnosed_with_breast_cancer_before_age_42_years_(Offit_et_al_1996)._In_the_Ashkenazi_Jewish_population,_the_variant_is_associated_with_a_risk_of_between_56%_and_83%_of_breast_cancer_and_of_between_14%_and_58%_risk_of_ovarian_cancer_by_the_age_of_70_(Struewing_et_al._1997:_Antoniou_et_al._2005:_Finkelman_et_al._2012)._The_variant_has_been_observed_in_individuals_of_other_ethnicities_(Wang_et_al._2012:_Laitman_et_al._2013)._The_variant_is_reported_at_a_frequency_of_0.00042_in_the_European_(Non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Based_on_the_available_evidence,_the_p.Glu23ValfsTer17_variant_is_classified_as_pathogenic_for_hereditary_breast_and_ovarian_cancer.|||||Variant_summary:_The_BRCA1_c.68_69delAG_(p.Glu23Valfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_of_interest_is_one_of_the_most_common_Jewish_founder_mutations._Multiple_publications_have_cited_the_variant_in_affected_individuals._This_variant_was_found_in_29/120972_control_chromosomes_at_a_frequency_of_0.0002397,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA1_variant_(0.0010005)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||Converted_during_submission_to_Pathogenic.|This_mutation_is_caused_by_the_deletion_of_two_nucleotides_(AG)_in_BRCA1_exon_2,_and_is_denoted_c.68_69delAG_at_the_cDNA_level_using_current_HGVS_nomenclature,_or_Glu23ValfsX16_at_the_protein_level._The_mutation_is_also_known_as_BRCA1_185delAG_or_187delAG_and_is_a_founder_mutation_in_the_Ashkenazi_Jewish_population_(Struewing_1995)._The_deletion_causes_a_frameshift,_which_changes_a_Glutamic_acid_to_a_Valine_at_codon_23_and_creates_a_premature_stop_codon_at_position_16_of_the_new_reading_frame._This_mutation_is_predicted_to_cause_loss_of_normal_protein_function_either_through_protein_truncation_or_nonsense-mediated_mRNA_decay_and_is_indicative_of_Hereditary_Breast_and_Ovarian_Cancer_(HBOC)_syndrome,_an_autosomal_dominant_condition_that_predisposes_to_breast_and_ovarian_cancer_as_well_as_other_cancers._The_predominant_BRCA1-related_cancer_risks_for_women_who_have_not_been_diagnosed_with_cancer_have_been_estimated_to_be_57%_-_84%_lifetime_risk_for_breast_cancer_and_24%_-_54%_lifetime_risk_for_ovarian_cancer_(Antoniou_2003,_Chen_2007,_Ford_1998)._BRCA1_mutations_have_also_been_reported_in_women_with_fallopian_tube_carcinoma,_primary_peritoneal_carcinoma,_and_uterine_serous_carcinoma_(Levine_2003,_Pennington_2013)._Women_with_BRCA1/2_mutations_also_have_an_increased_risk_for_contralateral_breast_cancer._Women_with_BRCA_mutations_whose_first_cancer_was_diagnosed_under_age_40_have_a_21-31%_risk_to_develop_a_second_breast_cancer_within_10_years_and_a_63%_risk_to_develop_a_second_breast_cancer_within_25_years._Women_with_BRCA_mutations_whose_first_cancer_was_diagnosed_between_ages_40_and_50_have_an_11-13%_risk_to_develop_a_second_breast_cancer_within_10_years_and_a_44-49%_risk_within_25_years._Women_with_BRCA_mutations_whose_first_cancer_was_diagnosed_after_age_50_have_an_8%_risk_to_develop_a_second_breast_cancer_within_10_years_and_a_20%_risk_within_25_years_(Graeser_2009)._Other_cancer_risks_associated_with_a_BRCA1_mutation_include_approximately_3%_risk_for_pancreatic_cancer_(The_Breast_Cancer_Linkage_Consortium_1999),_a_20%_risk_for_prostate_cancer_(Thompson_2002),_and_4%_risk_for_male_breast_cancer_(Liede_2004)._The_variant_is_found_in_BR-OV-HEREDIC,BRCA1-BRCA2,BRCA-AJ,HIRISK-BR-HEREDIC,HEREDICANCER_panel(s).|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_deletion_of_two_nucleotides_is_denoted_BRCA1_c.68_69delAG_at_the_cDNA_level_and_p.Glu23ValfsX17_(E23VfsX17)_at_the_protein_level._The_variant_is_also_known_as_BRCA1_185delAG_or_187delAG_using_alternate_nomenclature_and_is_one_of_three_main_pathogenic_founder_variants_in_the_Ashkenazi_Jewish_population_(Struewing_1995)._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TTAG[delAG]TGTC._The_deletion_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_a_Valine_at_codon_23,_and_creates_a_premature_stop_codon_at_position_17_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.||||||The_BRCA1_c.68_69delAG:_p.Glu23fs_variant_(rs386833395),_also_known_as_187delAG,_is_described_in_the_literature_as_a_known_common_cause_of_breast_and_ovarian_cancer_in_the_Ashkenazi_Jewish_population,_but_is_also_observed_in_other_ethnic_populations_in_individuals_with_breast,_ovarian,_and_pancreatic_cancer_(see_link_to_HGMD_database_and_references_therein)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_17662),_and_is_found_in_the_general_population_with_an_overall_allele_frequency_of_0.02%_(58/282,442_alleles)_in_the_Genome_Aggregation_Database._This_variant_causes_a_frameshift_by_deleting_2_nucleotides,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_the_p.Glu23fs_variant_is_considered_to_be_pathogenic._References:_Link_to_HGMD_database_(CD951600):_https://portal.biobase-international.com/hgmd/pro/mut.php?acc	TCGA_UCEC_459
NM_007294.3:c.4243del	BRCA1	chr17	41234535	-	9411bdaf-e59a-4884-b424-87193e1dfe94	frameshift_variant	-	-	-	-	37578	46134	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41234535del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2843562|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:190214|Breast_Cancer_Information_Core__(BRCA1):4362&base_change%3Ddel_G	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80357981	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|GeneDx|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-06-15|2003-07-22|2016-09-08|2015-10-02|2017-05-09|2018-03-29|2017-11-20|2018-03-06|2014-01-31|2014-12-10	2013-06-26|2014-03-28|2016-09-13|2016-10-28|2020-02-26|2019-01-29|2018-10-10|2018-08-31|2017-08-04|2017-04-19	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053759|SCV000145038|SCV000300095|SCV000325906|SCV000274996|SCV000566521|SCV000883469|SCV000888913|SCV000587384|SCV000591499	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_deletion_of_one_nucleotide_in_BRCA1_is_denoted_c.4243delG_at_the_cDNA_level_and_p.Glu1415LysfsX4_(E1415KfsX4)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA1_c.4362delG._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_ACTA[delG]AAGC._The_deletion_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_a_Lysine_at_codon_1415,_and_creates_a_premature_stop_codon_at_position_4_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_c.4243delG_has_been_observed_in_at_least_four_breast_and/or_ovarian_cancer_families_and_in_an_individual_with_endometrial_cancer_(Konecny_2011,_Smith_2011,_Lu_2015)._In_an_HDR_activity_assay,_BRCA1_c.4243delG_demonstrated_significantly_reduced_HDR_activity_relative_to_wild_type_(Lu_2015)._We_consider_this_variant_to_be_pathogenic.||||	TCGA_UCEC_462
NM_001128425.1:c.934-2A>G	MUTYH	chr1	45797760	C	b00c9ebb-b66a-4e09-8b14-9dd75301c2fa	splice_acceptor_variant	-	-	-	-	41766	50205	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_specified|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN169374|MedGen:CN517202	-	NC_000001.10:g.45797760T>C	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_benign(1),Likely_pathogenic(4),Pathogenic(1),Uncertain_significance(3)	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001574|splice_acceptor_variant	1	77542170	-	Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|Invitae|Soonchunhyang_University_Bucheon_Hospital,Soonchunhyang_University_Medical_Center|Mendelics|ITMI|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	probably_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|not_provided|Uncertain_significance|Uncertain_significance|Likely_benign|Likely_pathogenic|Likely_pathogenic|Uncertain_significance	2012-07-13|2019-01-02|2016-03-18|2018-07-02|2013-09-19|2017-09-01|2019-07-19|2019-03-29|2018-06-07|2018-12-18|2019-02-14	0000-00-00|2019-03-28|2016-04-14|2018-08-20|2014-05-29|2019-03-21|2019-09-24|2020-02-26|2018-11-06|2019-01-29|2020-03-06	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000043373|SCV000166463|SCV000267403|SCV000837758|SCV000083982|SCV000221200|SCV000697717|SCV000183748|SCV000910559|SCV000211414|SCV000601664	MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|not_specified|not_specified|not_specified|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	Converted_during_submission_to_Likely_pathogenic.|This_sequence_change_affects_an_acceptor_splice_site_in_intron_10._It_is_expected_to_disrupt_mRNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs77542170,_ExAC_1.4%)_with_an_elevated_carrier_frequency_in_the_Asian_population_(PMID:_24728327,_15180946,_17703316,_18271935)._This_variant_has_been_reported_as_heterozygous_in_several_individuals_with_colorectal_adenomas,_colorectal_carcinomas_(PMID:_15890374,_17703316),_and/or_breast_cancer_(PMID:_15890374,_17703316,_26824983)._In_all_of_these_individuals,_this_variant_was_the_only_pathogenic_variant_identified_for_this_typically_autosomal_recessive_gene._Importantly,_the_evidence_from_these_reports_is_insufficient_to_determine_whether_this_heterozygous_variant_alone_is_causative_for_disease._In_the_literature,_this_variant_is_also_known_as_c.892-2A>G_and_IVS10-2A>G._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_41766)._RNA_analysis_of_individuals_with_this_variant_indicates_that_it_leads_to_inclusion_of_intron_10_and_a_premature_termination_codon_(PTC)_in_the_MUTYH_mRNA_(PMID:_15180946)._While_a_PTC_is_expected_to_result_in_nonsense_mediated_decay_(NMD)_and_loss_of_the_mutant_mRNA,_protein_analysis_of_this_variant_indicates_that_a_truncated_MUTYH_protein_is_expressed,_but_preferentially_localized_to_the_cytoplasm_in_a_human_cell_line._Since_the_wild-type_MUTYH_protein_is_predominantly_localized_to_the_nucleus,_this_data_suggests_that_this_splice_site_variant_disrupts_protein_function._In_summary,_donor_and_acceptor_splice_site_variants_are_typically_truncating_(PMID:_16199547),_and_the_truncated_protein_generated_by_this_splice_site_variant_has_been_shown_to_behave_aberrantly_in_cell_culture_(PMID:_15180946)._This_evidence_strongly_suggests_that_the_variant_is_pathogenic,_but_the_available_data_is_currently_insufficient_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||||The_c.934-2A>G_variant_has_been_widely_studied_in_the_East_Asian_population_and_reported_in_at_least_7_individuals_with_colorectal_cancer:_however,_to_our_knowl_edge,_none_of_these_individuals_had_a_second_pathogenic_germline_MUTYH_variant_i_dentified_(Miyaki_2005,_Kim_2007,_Taki_2016)._This_variant_has_been_identified_i_n_1.6%_(294/18944)_of_East_Asian_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSNP_rs77542170)._The_c.934-2A>G_var_iant_occurs_in_the_invariant_region_(+/-_1,2)_of_the_splice_consensus_sequence_a_nd_was_demonstrated_to_cause_aberrant_splicing_in_in_vitro_studies_(Tao_2004,_Ta_ki_2016),_but_whether_this_alteration_causes_a_biological_loss_of_function_of_th_e_MUTYH_protein_in_humans_is_uncertain._In_summary,_while_the_predicted_function_al_impact_of_this_variant_and_in_vitro_studies_favor_a_pathogenic_role,_based_on_the_absence_of_reported_affected_individuals_carrying_this_variant_and_a_second_pathogenic_MUTYH_variant_in_the_literature_despite_its_high_frequency_in_the_ge_neral_population,_its_clinical_significance_is_uncertain._Additional_studies_are_needed_to_clarify_the_significance_of_this_variant.|Variant_summary:_MUTYH_c.934-2A>G_is_located_in_a_canonical_splice-site_and_is_predicted_to_affect_mRNA_splicing_resulting_in_a_significantly_altered_protein_due_to_either_exon_skipping,_shortening,_or_inclusion_of_intronic_material._Several_computational_tools_predict_a_significant_impact_on_normal_splicing:_Five_predict_the_variant_abolishes_a_3_prime_acceptor_site._Two_functional_studies_(Taki_2016_and_Tao_2004)_showed_that_the_variant_leads_to_formation_of_two_aberrant_mRNA_transcripts_that_retain_intron_10,_one_of_which_leads_to_a_premature_stop_codon_resulting_in_a_truncated_MUTYH_protein._In_addition,_Tao_2004_found_that_the_wild-type_MUTYH_protein,_but_not_the_truncated_protein,_is_localized_in_the_nucleus_suggesting_insufficient_ability_of_the_variant-type_to_repair_nuclear_DNA._The_variant_allele_was_found_at_a_frequency_of_0.0012_in_278868_control_chromosomes,_predominantly_at_a_frequency_of_0.016_within_the_East_Asian_subpopulation_in_the_gnomAD_database_and_publications,_including_5_homozygotes._The_observed_variant_frequency_within_East_Asian_control_individuals_in_the_gnomAD_database_is_approximately_3.5-fold_of_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_MUTYH_causing_MUTYH-associated_Polyposis_phenotype_(0.0046),_suggesting_that_this_might_be_a_moderate_penetrance_variant_found_primarily_in_populations_of_East_Asian_origin._The_variant,_c.934-2A>G,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_MUTYH-associated_Polyposis,_HBOC,_gallbladder,_colon,_and_thyroid_cancer_(Frey_2015,_Hansen_2017,_Hirotsu_2015,_Kim_2007,_Li_2017,_Miyaki_2005,_Taki_2016,_Zhang_2017,_Chan_2018)._These_data_indicate_that_the_variant_is_possibly_to_associate_with_disease._A_publication_(Jian_2017)_reports_two_independent_affected_BrC_patients_who_do_not_carry_the_variant_of_interest,_while_some_of_their_unaffected_daughters_(younger_than_the_average_age_of_onset_for_BrC,_50_years)_carried_the_variant._Case-control_studies_indicate_that_this_variant_may_be_associated_with_moderate_increase_in_risk_for_colorectal_cancer_(Tao_2008,_Yang_2013)._None_of_the_reported_individuals_with_colorectal_polyposis_were_indicated_to_be_compound_heterozygotes_or_homozygotes_for_MUTYH_mutations,_although_one_homozygote_patient_diagnosed_with_gastric_cancer_was_reported_(Tao_2004)._Co-occurrences_with_other_pathogenic_variants_have_been_reported_(APC_c.2751delT,_p.D917fs:_BRCA1_c.2110_2111delAA,_p.N704CfsX7:_APC_with_an_unspecified_deletion:_BRCA2_c.774_775delAA,_p.Glu260Serfs*15:_MLH1_c.704_723del,_p.Lys236Glufs*64)._Eight_other_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._Multiple_laboratories_reported_the_variant_with_conflicting_assessments_(likely_pathogenic/pathogenic_x6,_VUS_x2)._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_VUS-possibly_pathogenic.|Sub-population_frequency_in_support_of_benign_classification_(not_ava_blue,_manual_h-w):Other_data_supporting_benign_classification:RNA_Studies||This_variant_is_denoted_MUTYH_c.934-2A>G_or_IVS10-2A>G_and_consists_of_an_A>G_nucleotide_substitution_at_the_-2_position_of_intron_10_of_the_MUTYH_gene._Using_an_alternate_transcript,_this_variant_has_been_reported_as_MUTYH_c.892-2A>G._This_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._Tao_et_al._(2004)_and_Taki_et_al._(2015)_have_independently_shown_that_MUTYH_c.934-2A>G_results_in_an_aberrant_mRNA_transcript_which_retains_intron_10,_has_a_premature_stop_codon_in_exon_11,_and_encodes_a_truncated_protein._In_addition,_in_vitro_expression_studies_demonstrate_that,_if_translated,_the_variant_protein,_in_contrast_to_wild-type_expressed_protein,_is_not_localized_in_the_nucleus,_suggesting_insufficient_ability_of_the_variant_to_repair_nuclear_DNA_(Tao_2004)._However,_this_variant_has_not,_to_our_knowledge,_been_published_in_the_literature_in_the_homozygous_or_compound_heterozygous_state_in_an_individual_with_a_phenotype_consistent_with_MUTYH-associated_polyposis_(MAP)._MUTYH_c.934-2A>G_was_observed_at_an_allele_frequency_of_1.5%_(293/18,870)_in_individuals_of_East_Asian_ancestry_in_large_population_cohorts_(Lek_2016)_and_has_been_described_in_the_literature_as_a_common_variant_in_Japanese_individuals_(Tao_2004,_Miyaki_2005)._Based_on_currently_available_evidence,_we_consider_MUTYH_c.934-2A>G_to_be_a_likely_pathogenic_variant.|	TCGA_UCEC_468
NM_000314.4:c.750_751del	PTEN	chr10	89717719	-	b9ea346c-6313-4b27-ba7d-46b85ecaddf5	frameshift_variant	-	-	-	-	404156	397948	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498	-	NC_000010.10:g.89717719_89717720TG[3]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	PTEN:5728	SO:0001589|frameshift_variant	1	780264945	-	Invitae|Ambry_Genetics	Pathogenic|Pathogenic	2018-05-01|2014-08-05	2018-08-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000541605|SCV000579962	PTEN_hamartoma_tumor_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Cys250Trpfs*2)_in_the_PTEN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_has_been_reported_in_an_individual_with_Cowden_or_Cowden-like_syndrome_(PMID:_25669429).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 404156)._Loss-of-function_variants_in_PTEN_are_known_to_be_pathogenic_(PMID:_9467011,_21194675)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)	TCGA_UCEC_478
NM_000251.2:c.1276+2T>C	MSH2	chr2	47657082	C	7080a741-bc78-454b-81a7-f93e9411c6cf	splice_donor_variant	-	-	-	-	218032	214582	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome_I|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2936783,OMIM:120435|MedGen:CN517202	-	NC_000002.11:g.47657082T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MSH2:4436	SO:0001575|splice_donor_variant	1	267607953	-	Mayo_Clinic|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Ambry_Genetics|Counsyl	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	0000-00-00|2018-10-23|2016-12-23|2017-08-08|2018-10-29|2016-12-14	2015-11-19|2019-01-29|2017-08-01|2018-04-02|2020-02-26|2017-06-22	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline|unknown	SCV000257131|SCV000292623|SCV000601428|SCV000548099|SCV000580619|SCV000677828	not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome_I	|This_pathogenic_variant_is_denoted_MSH2_c.1276+2T>C_or_IVS7+2T>C_and_consists_of_a_T>C_nucleotide_substitution_at_the_+2_position_of_intron_7_of_the_MSH2_gene._The_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature._Based_on_the_current_evidence,_we_consider_MSH2_c.1276+2T>C_to_be_pathogenic.||This_sequence_change_affects_a_donor_splice_site_in_intron_7_of_the_MSH2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs267607953,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_MSH2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_218032)._A_different_variant_affecting_this_nucleotide_(c.1276+2T>A)_has_been_determined_to_be_pathogenic_(PMID:_16395668,_21642682)._This_suggests_that_this_nucleotide_is_important_for_normal_RNA_splicing,_and_that_other_variants_at_this_position_may_also_be_pathogenic._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_MSH2_are_known_to_be_pathogenic_(PMID:_15849733,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|	TCGA_UCEC_506
NM_006363.4:c.649C>T	SEC23B	chr20	18505624	T	b4aa278e-adfe-48e3-8a92-f5057f05f941	stop_gained	5&5	0&1	rs121918226	Congenital dyserythropoietic anemia, type II&not provided	1227	16266	_type_II|not_provided	-	MedGen:C1306589,OMIM:224100,Orphanet:ORPHA98873,SNOMED_CT:68870007|MedGen:CN517202	-	NC_000020.10:g.18505624C>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	HGMD:CM094614|OMIM_Allelic_Variant:610512.0006	-	SEC23B:10483	SO:0001587|nonsense	1	121918226	-	Eurofins_Clinical_Diagnostics	Pathogenic|Pathogenic	2009-09-01|2014-01-30	2018-07-11|2018-09-19	_single_submitter	germline|germline	SCV000021436|SCV000203543	_type_II|not_provided	|	TCGA_UCEC_528
NM_007194.3:c.1283C>T	CHEK2	chr22	29091207	A	a693ad84-d47d-4181-a04c-0b25df5e4ba0	missense_variant	5&5&5&5	2&1&1&1	rs137853011	Hereditary cancer-predisposing syndrome&Familial cancer of breast&Breast and colorectal cancer, susceptibility to&not provided	5603	20642	Osteosarcoma|Malignant_tumor_of_prostate|Neoplasm_of_the_breast|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Colorectal_cancer|Li-Fraumeni_syndrome_2|Breast_and_colorectal_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|CHEK2-Related_Cancer_Susceptibility|not_provided	-	Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1527249|MedGen:C1836482,OMIM:609265|MedGen:C1858433|MedGen:C3469522|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29091207G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(5),Pathogenic(11),Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	Illumina:203534|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2833351|OMIM_Allelic_Variant:604373.0014|UniProtKB_(protein):O96017#VAR_022463	-	CHEK2:11200	SO:0001583|missense_variant	1	137853011	-	OMIM|Genetic_Services_Laboratory,_University_of_Chicago|Ambry_Genetics|Color|GeneKor_MSA|Invitae|Counsyl|Mendelics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Illumina_Clinical_Services_Laboratory,Illumina|Illumina_Clinical_Services_Laboratory,Illumina|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|Illumina_Clinical_Services_Laboratory,Illumina	risk_factor|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2005-02-15|2017-02-21|2019-10-30|2015-02-16|2018-08-01|2019-01-08|2017-05-22|2018-07-02|2017-06-05|2015-11-20|2019-01-02|2019-03-22|2018-06-01|2016-06-14|2016-06-14|2017-05-18|2019-01-15|2017-09-05	2017-11-21|2017-07-05|2020-02-26|2016-07-05|2018-08-08|2019-03-28|2017-06-22|2018-08-20|2018-06-14|2016-03-03|2019-01-29|2020-03-06|2019-07-12|2016-10-18|2016-10-18|2017-05-23|2019-09-24|2019-02-01	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000026135|SCV000594114|SCV000187227|SCV000292126|SCV000821728|SCV000253983|SCV000677740|SCV000839461|SCV000839938|SCV000266068|SCV000149903|SCV000601148|SCV000892318|SCV000437716|SCV000437715|SCV000611259|SCV000698769|SCV000914987	Breast_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and_colorectal_cancer,_susceptibility_to|not_provided|not_provided|not_provided|Colorectal_cancer|Neoplasm_of_the_breast|Familial_cancer_of_breast/Li-Fraumeni_syndrome_2/Osteosarcoma/Malignant_tumor_of_prostate|Hereditary_breast_and_ovarian_cancer_syndrome|CHEK2-Related_Cancer_Susceptibility	||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Significant_disease_association_in_appropriately_sized_case-control_study(ies):Good_segregation_with_disease_(lod_1.5-3_	TCGA_UCEC_044
NM_058216.2:c.965+5G>A	RAD51C	chr17	56801466	A	f11f0b5e-0e7a-4766-bbb4-f832af2871bd	splice_region_variant,intron_variant	-	-	-	-	409841	402642	_complementation_group_O	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390	-	NC_000017.10:g.56801466G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(2)	-	single_nucleotide_variant	SO:0001483	-	-	RAD51C:5889	SO:0001627|intron_variant	1	774586107	-	Invitae|Ambry_Genetics|Color	Uncertain_significance|Likely_pathogenic|Uncertain_significance	2016-06-04|2018-05-30|2018-08-24	2017-03-14|2020-02-26|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000550196|SCV000663788|SCV000686408	_complementation_group_O|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_variant_affects_a_highly_conserved_nucleotide_within_the_consensus_splice_site_of_intron_7._The_majority_of_introns_(75%)_have_a_G_nucleotide_at_this_position_(PMID:_9536098)._This_variant_is_present_in_population_databases_(rs774586107,_ExAC_0.002%)._This_variant_has_been_reported_in_in_an_individual_affected_with_ovarian_cancer_(PMID:_22725699)._RT-PCR_analysis_of_mRNA_isolated_from_patient_blood_cells_showed_that_this_variant_leads_to_skipping_of_exon_7_(PMID:_22725699)._In_summary,_this_variant_has_been_reported_in_both_the_population_and_in_an_affected_individual,_and_it_is_likely_to_cause_a_splicing_defect._However,_without_additional_functional_and/or_genetic_data,_this_variant_has_been_classified_as_a_Variant_of_Uncertain_Significance.|Functionally-validated_splicing_mutation:Other_strong_data_supporting_pathogenic_classification:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|	TCGA_UCEC_061
NM_001128425.1:c.1187G>A	MUTYH	chr1	45797228	T	694952b1-ac9e-4274-9007-301ae55d3c35;f54e274d-b979-4d0a-b8be-ab1ae91a3650;c7003b8a-d13b-48df-adfa-2100ed264f8e;e6add426-17ca-4a1d-9013-b28532df9172;ce0bb973-2c1d-40e9-8966-c6259b745942;560c247f-7aba-421e-8fd6-22f8a910c8f9	missense_variant,splice_region_variant	5&5&5&5&5	2&0&2&2&0	rs36053993	MYH-associated polyposis&Endometrial carcinoma&not provided&Hereditary cancer-predisposing syndrome&Carcinoma of colon	5294	20333	Small_intestine_carcinoid|Neoplasm_of_stomach|Pilomatrixoma|Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|Colorectal_adenomatous_polyposis,_autosomal_recessive,_with_pilomatricomas|not_specified|endometrial_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0006722,MedGen:C1868072|Human_Phenotype_Ontology:HP:0006753,MeSH:D013274,MedGen:C0038356,OMIM:613659,SNOMED_CT:126824007|Human_Phenotype_Ontology:HP:0030434,MeSH:D018296,MedGen:C0206711,OMIM:132600,Orphanet:ORPHA91414|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:C4016911|MedGen:CN169374|MedGen:CN235594|MedGen:CN517202	-	NC_000001.10:g.45797228C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Center_for_Human_Genetics,_Inc:MUTYH-A4|Donald_Williams_Parsons_Laboratory,Baylor_College_of_Medicine:851773|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2010|HGMD:CM020287|OMIM_Allelic_Variant:604933.0002	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	36053993	-	OMIM|Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|GeneReviews|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Donald_Williams_Parsons_Laboratory,Baylor_College_of_Medicine|Counsyl|Center_for_Human_Genetics,_Inc|Mendelics|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|OMIM|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Vantari_Genetics|Color|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|True_Health_Diagnostics|GeneKor_MSA|ITMI|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Pathway_Genomics|Division_of_Human_Genetics,Children's_Hospital_of_Philadelphia|Endocrine_oncology_group,Uppsala_University|Genetic_Services_Laboratory,_University_of_Chicago|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|GenomeConnect,_ClinGen	Pathogenic|pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided	2011-09-01|2012-07-13|2019-10-08|2019-01-11|2015-03-04|2016-11-09|2015-10-12|2015-07-01|2016-11-01|2018-07-02|2019-12-18|2011-09-01|2018-02-27|2018-10-29|2016-08-15|0000-00-00|2016-03-22|2019-07-31|2015-11-20|2015-12-21|2016-02-16|2018-05-23|2017-12-29|2018-08-01|2013-09-19|2018-08-01|2014-07-24|2015-06-04|2017-03-09|2016-08-26|2017-05-18|2017-08-09|0000-00-00	2019-08-20|0000-00-00|2019-12-13|2019-03-28|2019-03-21|2017-04-19|2016-08-18|2017-06-22|2017-12-20|2018-08-20|2019-12-18|2019-08-20|2018-09-19|2019-01-29|2018-08-31|2017-10-31|2018-01-29|2020-02-26|2016-03-03|2016-03-29|2017-01-26|2018-05-23|2018-03-08|2018-08-08|2014-05-29|2019-08-05|2014-08-08|2017-01-23|2017-06-12|2017-07-05|2017-05-23|2018-01-25|2018-03-13	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided	germline|germline|germline|germline|germline|germline|germline|unknown|germline|unknown|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|unknown	SCV000025796|SCV000043370|SCV000057867|SCV000166443|SCV000245638|SCV000592711|SCV000599972|SCV000678192|SCV000781800|SCV000837751|SCV000993433|SCV000025797|SCV000111383|SCV000149657|SCV000601628|SCV000691947|SCV000806339|SCV000184573|SCV000266099|SCV000267061|SCV000537630|SCV000679736|SCV000788060|SCV000821744|SCV000085795|SCV000604306|SCV000189964|SCV000536693|SCV000536689|SCV000595873|SCV000611285|SCV000697670|SCV000840099	MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|endometrial_cancer|not_provided|not_provided|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|Carcinoma_of_colon|MYH-associated_polyposis/Neoplasm_of_stomach|Small_intestine_carcinoid|Colorectal_adenomatous_polyposis,_autosomal_recessive,_with_pilomatricomas|MYH-associated_polyposis/Pilomatrixoma/Neoplasm_of_stomach|MUTYH-associated_polyposis|MUTYH-associated_polyposis	|Converted_during_submission_to_Pathogenic.||This_sequence_change_replaces_glycine_with_aspartic_acid_at_codon_396_of_the_MUTYH_protein_(p.Gly396Asp)._The_glycine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_glycine_and_aspartic_acid._This_variant_is_a_known_common_cause_of_MUTYH-associated_polyposis_(PMID:_23035301)._This_variant_has_been_reported_to_co-segregate_with_disease_in_individuals_affected_with_colorectal_cancer,_familial_adenomatous_polyposis_(FAP),_and_attenuated_FAP_(PMID:_11818965,_16557584,_17489848,_19793053).Â¬â€ This_variant_is_also_known_as_c.1145G>A_(p.Gly382Asp)_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_5294)._MUTYH-related_conditions_are_inherited_in_an_autosomal_recessive_fashion._However,_there_is_evidence_that_monoallelic_pathogenic_MUTYH_variants_including_this_particular_variant_are_associated_with_increased_risk_of_colon_cancer_(PMID:_16492921,_19394335,_21171015,_24444654,_15931596)._Experimental_studies_have_shown_that_this_missense_change_disrupts_MUTYH_protein_function_(PMID:_15987719,_18534194,_20848659,_23108399)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Gly396Asp_variant_in_MUTYH_is_a_well-established_pathogenic_variant_for_MU_TYH-related_attenuated_familial_adenomatous_polyposis_and_is_estimated_to_accoun_t_for_50-82%_of_MUTYH-associated_polyposis_in_European_patients_(Al-Tassan_2002,_Nielsen_2009,_Vogt_2009,_Nascimbeni_2010,_Aretz_2014,_ClinVar:_Variation_ID_529_4)._In_vitro_functional_studies_provide_some_evidence_that_the_p.Gly396Asp_varia_nt_may_impact_protein_function_(Al-Tassan_2002,_Ali_2008,_Goto_2010)._This_vari_ant_has_also_been_identified_in_0.5%_(608/126146)_of_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org/:_dbSNP_r_s36053993):_however,_this_frequency_is_low_enough_to_be_consistent_with_a_recess_ive_carrier_frequency._Computational_prediction_tools_and_conservation_analysis_suggest_that_the_p.Gly396Asp_variant_may_impact_the_protein._In_summary,_this_va_riant_meets_criteria_to_be_classified_as_pathogenic_for_MUTYH-associated_polypos_is_in_an_autosomal_recessive_manner._ACMG/AMP_Criteria_applied:_PM3_VeryStrong,_PP3,_PS3_Supporting.||This_variant_has_been_previously_reported_as_disease-causing._It_would_be_pathogenic_in_a_recessive_state:_heterozygotes_would_be_carriers_for_the_condition._It_was_found_once_in_our_study_heterozygous_in_a_6-year-old_male_with_anaplastic_ganglioglioma.|||||||This_pathogenic_variant_is_denoted_MUTYH_c.1187G>A_at_the_cDNA_level,_p.Gly396Asp_(G396D)_at_the_protein_level,_and_results_in_the_change_of_a_Glycine_to_an_Aspartic_Acid_(GGT>GAT)._MUTYH_Gly396Asp,_also_annotated_as_Gly382Asp_using_a_different_gene_transcript,_is_one_of_two_common_MUTYH_pathogenic_variants_which_together_account_for_up_to_80%_of_pathogenic_MUTYH_variants._It_has_been_observed_in_the_homozygous_and_compound_heterozygous_state_in_multiple_individuals_with_MUTYH-Associated_Polyposis,_including_affected_siblings_(Al-Tassan_2002,_de_Leon_2017,_Yurgelun_2017)._Multiple_in_vitro_functional_studies_demonstrate_this_variant's_pathogenic_effect_(Al-Tassan_2002,_Ali_2008,_Goto_2010)._MUTYH_Gly396Asp_was_observed_at_an_allele_frequency_of_0.48%_(611/126146)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_8-oxo-G_binding_site_within_the_Nudix_domain_(Ruggieri_2013)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._We_consider_this_variant_to_be_pathogenic.||||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Other_strong_data_supporting_pathogenic_classification||||||||The_MUTYH_c.1187G>A:_p.Gly396Asp_variant_(rs36053993:_also_known_as_NM_001048171.1:_c.1145G>A:_p.Gly382Asp)_has_been_well_described_in_the_literature_as_one_of_the_two_common_MUTYH_pathogenic_variants._It_has_been_observed_in_homozygous_or_compound_heterozygous_form_with_other_pathogenic_MUTYH_variants_in_patients_with_adenomatous_polyposis_syndrome_(Al-Tassan_2002,_Nielsen_2009,_Ruggieri_2013),_and_is_enriched_in_patients_with_an_odds_ratio_of_6.47_(Theodoratou_2010)._Functional_characterization_of_the_variant_protein_indicates_a_partial_reduction_in_DNA_binding_and_glycosylase_activity_(Ali_2008,_D'Agostino_2010,_Goto_2010,_Komine_2015,_Kundu_2009,_Molatore_2010,_Ruggieri_2013)._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Ali_M_et_al._Characterization_of_mutant_MUTYH_proteins_associated_with_familial_colorectal_cancer._Gastroenterology._2008_135(2):499-507._Al-Tassan_N_et_al._Inherited_variants_of_MYH_associated_with_somatic_G:C-->T:A_mutations_in_colorectal_tumors._Nat_Genet._2002_30(2):227-32._D'Agostino_V_et_al._Functional_analysis_of_MUTYH_mutated_proteins_associated_with_familial_adenomatous_polyposis._DNA_Repair_(Amst)._2010_9(6):700-7._Goto_M_et_al._Adenine_DNA_glycosylase_activity_of_14_human_MutY_homolog_(MUTYH)_variant_proteins_found_in_patients_with_colorectal_polyposis_and_cancer._Hum_Mutat._2010_31(11):E1861-74._Komine_K_et_al._Functional_Complementation_Assay_for_47_MUTYH_Variants_in_a_MutY-Disrupted_Escherichia_coli_Strain._Hum_Mutat._2015_36(7):704-11._Kundu_S_et_al._Adenine_removal_activity_and_bacterial_complementation_with_the_human_MutY_homologue_(MUTYH)_and_Y165C,_G382D,_P391L_and_Q324R_variants_associated_with_colorectal_cancer._DNA_Repair_(Amst)._2009_8(12):1400-10._Molatore_S_et_al._MUTYH_mutations_associated_with_familial_adenomatous_polyposis:_functional_characterization_by_a_mammalian_cell-based_assay._Hum_Mutat._2010_31(2):159-66._Nielsen_M_et_al._Analysis_of_MUTYH_genotypes_and_colorectal_phenotypes_in_patients_With_MUTYH-associated_polyposis._Gastroenterology._2009_136(2):471-6._Ruggieri_V_et_al._Loss_of_MUTYH_function_in_human_cells_leads_to_accumulation_of_oxidative_damage_and_genetic_instability._Oncogene._2013_32(38):4500-8._Theodoratou_E_et_al._A_large-scale_meta-analysis_to_refine_colorectal_cancer_risk_estimates_associated_with_MUTYH_variants._Br_J_Cancer._2010_Dec_7:103(12):1875-84.||||||Variant_summary:_The_MUTYH_c.1187G>A_(p.Gly396Asp)_variant_involves_the_alteration_of_a_conserved_nucleotide._3/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant._Functional_studies_support_a_damaging_outcome,_and_at_least_2_independent_labs_have_down_reduced_DNA_glycosylase_activity_and_a_reduced_ability_to_suppress_the_mutation_frequency_in_a_complementation_assay._This_variant_was_found_in_339/120440_control_chromosomes_(2_homozygotes)_at_a_frequency_of_0.0028147,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MUTYH_variant_(0.0045644)._The_variant_has_been_reported_in_numerous_patients_in_the_literature,_and_is_known_as_a_common_pathogenic_variant._In_addition,_many_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.	TCGA_UCEC_062;TCGA_UCEC_185;TCGA_UCEC_259;TCGA_UCEC_288;TCGA_UCEC_300;TCGA_UCEC_491
NM_007194.3:c.1427C>T	CHEK2	chr22	29090054	A	cac37549-d384-4344-8658-fdfb56dd7524	missense_variant	4&4	1&1	rs142763740	Hereditary cancer-predisposing syndrome&not provided	128060	133517	_susceptibility_to|not_specified|CHEK2-Related_Cancer_Susceptibility|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1527249|MedGen:C1858433|MedGen:CN169374|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29090054G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(8)	-	single_nucleotide_variant	SO:0001483	Illumina:655839	-	CHEK2:11200	SO:0001583|missense_variant	17	142763740	-	Ambry_Genetics|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|GeneID_Lab_-_Advanced_Molecular_Diagnostics|Color|GeneKor_MSA|Invitae|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Counsyl|Mendelics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|PreventionGenetics,PreventionGenetics|Illumina_Clinical_Services_Laboratory,Illumina|Illumina_Clinical_Services_Laboratory,Illumina|Genetic_Services_Laboratory,_University_of_Chicago|Illumina_Clinical_Services_Laboratory,Illumina	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic	2019-08-16|2017-02-14|2017-09-07|2018-10-03|2018-08-01|2018-12-30|2018-04-16|2017-10-06|2018-07-02|2015-11-20|2019-01-07|2018-12-10|2016-10-14|2016-09-30|2016-06-14|2016-06-14|2016-11-21|2017-04-27	2020-02-26|2017-02-16|2017-09-11|2018-11-06|2018-08-08|2019-03-28|2018-05-24|2018-06-20|2018-08-20|2016-03-03|2019-01-29|2020-03-06|2018-01-25|2018-01-29|2016-10-18|2016-10-18|2017-07-05|2019-02-01	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000186804|SCV000576430|SCV000680448|SCV000689655|SCV000821724|SCV000254925|SCV000778585|SCV000785095|SCV000839455|SCV000266166|SCV000149910|SCV000601155|SCV000698777|SCV000806869|SCV000437713|SCV000437714|SCV000594113|SCV000914986	_susceptibility_to|not_provided|not_provided|not_provided|not_provided|Colorectal_cancer|Neoplasm_of_the_breast|not_specified|CHEK2-Related_Cancer_Susceptibility	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)|||||This_sequence_change_replaces_threonine_with_methionine_at_codon_476_of_the_CHEK2_protein_(p.Thr476Met)._The_threonine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_threonine_and_methionine._This_variant_is_present_in_population_databases_(rs142763740,_ExAC_0.07%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_21244692),_endometrial_cancer_(PMID:_27443514),_colorectal_cancer_(PMID:Â¬â€ 28944238),_prostate_cancer_(PMID:Â¬â€ 29368341,Â¬â€ 29520813),_and_in_a_male_with_breast_and_colon_cancer_(PMID:_28008555)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128060)._Experimental_studies_have_shown_that_this_missense_change_disrupts_CHEK2_kinase_activity_in_vitro_and_impairs_DNA_damage_response_in_a_yeast_assay_(PMID:_22114986,_22419737)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||||This_variant_is_denoted_CHEK2_c.1427C>T_at_the_cDNA_level,_p.Thr476Met_(T476M)_at_the_protein_level,_and_results_in_the_change_of_a_Threonine_to_a_Methionine_(ACG>ATG)._This_variant_has_been_reported_in_individuals_with_a_personal_and/or_family_history_of_breast,_pancreatic,_or_prostate_cancer_(Desrichard_2011,_Le_Calvez-Kelm_2011,_Hu_2015,_Leedom_2016,_Pritzlaff_2016,_Shirts_2016,_Frey_2017,_Isaacsson_Velho_2018,_Schubert_2018,_Wu_2018)._This_variant_was_shown_in_an_in_vitro_study_to_abolish_kinase_activity,_and_was_shown_in_an_in_vivo_study_to_impair_CHEK2-mediated_response_to_DNA_damage_(Desrichard_2011,_Roeb_2012)._A_different_nucleotide_change_(CHEK2_c.1427C>A)_resulting_in_the_same_amino_acid_substitution_was_identified_in_a_patient_with_a_clinical_diagnosis_of_Li-Fraumeni_syndrome_(Sadri_2014)._Although_this_variant_was_observed_in_large_population_cohorts,_population_data_in_this_region_of_CHEK2_are_not_considered_reliable_due_to_high_pseudogene_homology_(Lek_2016)._CHEK2_Thr476Met_is_located_in_the_protein_kinase_domain_(Cai_2009,_Roeb_2012)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_the_currently_available_evidence,_we_consider_CHEK2_Thr476Met_to_be_a_likely_pathogenic_variant.|The_best_available_variant_frequency_is_uninformative._Statistically_enriched_in_patients_compared_to_ethnically_matched_controls._Found_in_at_least_one_symptomatic_patient._Predicted_to_have_a_damaging_effect_on_the_protein._Occurs_in_a_single_case_with_an_otherwise_positive_result._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.||||Across_three_studies,_the_c.1427C>T_(p.Thr476Met),_was_reported_in_five_of_1,955_breast_cancer_patients_(Le_Calvez-Kelm_et_al._2011:_Desrichard_et_al._2011:_Angelova_et_al._2012)._The_variant_was_absent_from_a_total_of_1,622_controls,_but_is_reported_at_a_frequency_of_0.00068_in_the_European_(Non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Desrichard_et_al._(2011)_developed_an_in_vitro_kinase_activity_assay_to_assess_the_activity_of_missense_variants_in_CHEK2._In_this_assay_the_p.Thr476Met_variant_demonstrated_no_kinase_activity_and_was_similar_to_a_known_non-functional_kinase_variant_of_CHEK2._In_addition,_Roeb_et_al._(2012)_developed_a_yeast-based_in-vivo_functional_assay_to_assess_the_effect_of_CHEK2_variants_on_the_repair_of_DNA_damage._Cells_with_wild-type_CHEK2_repaired_the_DNA_damage_while_cells_with_a_known_non-functional_variant_of_CHEK2_did_not._The_p.Thr476Met_variant_was_shown_to_have_loss_of_function_by_this_DNA_damage_response_assay._Based_on_the_evidence,_the_p.Thr476Met_variant_is_classified_as_likely_pathogenic_for_breast_cancer.||The_CHEK2_c.1427C>T_(p.Thr476Met)_missense_variant,_also_referred_to_as_c.1556C>T_(p.Thr519Met),_was_reported_in_five_of_1,955_breast_cancer_patients_(Le_Calvez-Kelm_et_al._2011:_Desrichard_et_al._2011:_Angelova_et_al._2012)._The_variant_was_absent_from_a_total_of_1,622_controls,_but_is_reported_at_a_frequency_of_0.00068_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Desrichard_et_al._(2011)_developed_an_in_vitro_kinase_activity_assay_to_assess_the_activity_of_missense_variants_in_CHEK2._In_this_assay_the_p.Thr476Met_variant_demonstrated_no_kinase_activity_and_was_similar_to_a_known_non-functional_kinase_variant_of_CHEK2._In_addition,_Roeb_et_al._(2012)_developed_a_yeast-based_in-vivo_functional_assay_to_assess_the_effect_of_CHEK2_variants_on_the_repair_of_DNA_damage._Cells_with_wild_type_CHEK2_repaired_the_DNA_damage_while_cells_with_a_known_non-functional_variant_of_CHEK2_did_not._The_p.Thr476Met_variant_was_shown_to_have_loss_of_function_by_this_DNA_damage_response_assay._Based_on_the_evidence,_the_p.Thr476Met_variant_is_classified_as_pathogenic_for_CHEK2-related_cancer_susceptibility._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.	TCGA_UCEC_160
NM_032043.2:c.3208del	BRIP1	chr17	59761199	-	766abfdb-6fcc-4650-9805-66f8006ad479	frameshift_variant	-	-	-	-	461046	467113	_complementation_group_J	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054	-	NC_000017.10:g.59761199del	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	748598593	-	Invitae|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic	2017-11-13|2018-07-18	2018-04-02|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000633515|SCV001180562	_complementation_group_J|Hereditary_cancer-predisposing_syndrome	This_sequence_change_deletes_1_nucleotide_from_exon_20_of_the_BRIP1_mRNA_(c.3208delT),_causing_a_frameshift_at_codon_1070._This_creates_a_premature_translational_stop_signal_in_the_last_exon_of_the_BRIP1_mRNA_(p.Ser1070Glnfs*8)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_179_amino_acids_of_the_BRIP1_protein._This_variant_is_present_in_population_databases_(rs748598593,_ExAC_0.01%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRIP1-related_disease._This_truncation_affects_the_TopBP1-binding_region_(residues_1130-1153)_of_the_BRIP1_protein._It_is_expected_to_disrupt_the_TopBP1-BRIP1_interaction_that_plays_a_critical_role_in_RPA_chromatin_loading_following_DNA_replication_stress_and_the_subsequent_activation_of_the_replication_checkpoint_in_response_to_DNA_damage_(PMID:_20159562,_21127055)._In_summary,_this_variant_that_is_expected_to_disrupt_a_region_that_is_essential_for_BRIP1_protein_function._This_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_is_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_data_supporting_pathogenic_classification	TCGA_UCEC_173
NM_001128425.1:c.1437_1439del	MUTYH	chr1	45796891	-	a9cd1596-89b6-46fd-9864-8a62f47d1f8b	inframe_deletion	-	-	-	-	127838	133295	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_specified|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN169374|MedGen:CN517202	-	NC_000001.10:g.45796892_45796894CCT[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	Illumina:576414	-	MUTYH:4595	SO:0001822|inframe_deletion	1	587778541	-	Ambry_Genetics|Color|GeneKor_MSA|ITMI|Invitae|GeneReviews|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Illumina_Clinical_Services_Laboratory,Illumina|Counsyl|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Mendelics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-05-14|2016-08-04|2018-08-01|2013-09-19|2019-01-05|2019-10-08|2015-09-14|2016-06-14|2016-01-08|0000-00-00|2018-05-08|2018-07-02|2018-10-01|2017-01-20|2017-09-14	2020-02-26|2017-10-26|2018-08-08|2014-05-29|2019-03-28|2019-12-13|2019-03-21|2016-10-18|2016-11-23|2017-04-19|2019-08-01|2018-08-20|2019-01-29|2018-08-31|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|unknown|unknown|germline|germline|germline	SCV000184946|SCV000685578|SCV000821745|SCV000085796|SCV000166448|SCV000246168|SCV000271402|SCV000357889|SCV000487331|SCV000592718|SCV000778607|SCV000837745|SCV000149667|SCV000601634|SCV000917798	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|not_provided|not_provided|MUTYH-associated_polyposis	Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Other_strong_data_supporting_pathogenic_classification_:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||||This_sequence_change_deletes_3_nucleotides_from_exon_14_of_the_MUTYH_mRNA_(c.1437_1439delGGA)._This_leads_to_the_deletion_of_1_amino_acid_residue_in_the_MUTYH_protein_(p.Glu480del)_but_otherwise_preserves_the_integrity_of_the_reading_frame._This_variant_is_present_in_population_databases_(rs587778541,_ExAC_0.02%)._This_variant_is_a_known_common_cause_of_MUTYH-associated_polyposis_(PMID:_23035301)._It_has_been_reported_to_co-segregate_with_disease_in_individuals_affected_with_colorectal_cancer,_familial_adenomatous_polyposis_(FAP),_or_attenuated_FAP_(PMID:_14999774,_15635083,_12707038,_19527492,_16134147,_19732755)._This_variant_is_also_known_as_c.1395_1397delGGA,_c.1395delGGA,_Glu466del,_E466del_and_452delEÂ¬â€ in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127838)._Experimental_studies_have_shown_that_this_in-frame_deletion_disrupts_MUTYH_protein_function_(PMID:_23108399,_20848659,_20418187)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Glu480del_variant_in_MUTYH_(previously_reported_as_p.Glu466del_or_c.1395__1397delGGA)_has_been_reported_in_more_than_15_individuals_with_MUTYH-associated_polyposis_either_as_homozygous_or_compound_heterozygous_with_another_MUTYH_varia_nt,_and_segregated_with_disease_in_at_least_6_affected_family_members_from_3_fam_ilies_(Halford_2003,_Gismondi_2004,_Di_Gregorio_2006,_Vogt_2009,_Buisine_2013)._This_variant_is_a_deletion_of_the_glutamate_residue_(Glu)_at_position_480_and_is_not_predicted_to_alter_the_protein_reading-frame._In_vitro_functional_studies_p_rovide_some_evidence_that_the_p.Glu480del_variant_may_impact_protein_function_(D_agostino_2010,_Goto_2010,_Molatore_2010)._This_variant_has_also_been_identified_in_10/66728_European_and_4/16512_of_South_Asian_chromosomes_by_the_Exome_Aggrega_tion_Consortium,_including_one_homozygote_(ExAC,_http://exac.broadinstitute.org)_._Please_note_that_variants_associated_with_diseases_that_have_reduced_penetranc_e_and_late_age-of-onset_may_be_present_at_a_low_frequency_in_large_population_st_udies:_therefore_the_frequency_of_this_variant_is_consistent_with_the_known_prev_alance_and_penetrance_of_this_disease._In_summary,_this_variant_meets_our_criter_ia_to_be_classified_as_pathogenic_for_MUTYH-associated_familial_polyposis_in_an_autosomal_recessive_manner_(http://www.partners.org/personalizedmedicine/LMM)_ba_sed_upon_its_frequency_in_patients,_segregation_studies,_and_functional_evidence_.|The_c.1395_1397delGGA_(p.Glu466del)_variant_is_an_in-frame_deletion_variant_that_has_been_reported_extensively_in_the_literature._Across_a_selection_of_the_available_literature,_the_p.Glu466del_variant_has_been_observed_in_polyposis_or_colon_cancer_patients,_including_in_one_patient_in_a_homozygous_state,_eight_patients_in_a_compound_heterozygous_state,_and_one_patient_in_a_heterozygous_state_(Halford_et_al._2003:_Gismondi_et_al._2004:_Peterlongo_et_al._2006:_DeLellis_et_al._2013)._The_p.Glu466del_variant_was_absent_from_1,019_healthy_control_individuals_but_is_reported_at_a_frequency_of_0.00024_in_the_South_Asian_population_of_the_Exome_Aggregation_Consortium._In_vitro_testing_demonstrated_that_the_p.Glu466del_variant_was_dysfunctional_in_base_excision_repair_and_had_severely_impaired_enzymatic_activity_(Molatore_et_al._2010:_D'Agostino_et_al._2010:_Komine_et_al._2015)._Based_on_the_collective_evidence,_the_p.Glu466del_variant_is_classified_as_pathogenic_for_MYH-associated_polyposis.|||||This_pathogenic_variant_is_denoted_MUTYH_c.1437_1439delGGA_at_the_cDNA_level_and_p.Glu480del_(E480del)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AGGA[delGGA]ATTT._This_in_frame_deletion_of_three_nucleotides_results_in_the_loss_of_a_single_Glutamic_Acid_that_is_located_in_the_Nudix_hydrolase_domain_(Ruggieri_2013,_UniProt)._MUTYH_Glu480del,_also_denoted_as_1395_1397delGGA_and_466delE_using_alternate_nomenclature,_has_been_published_in_the_literature_as_an_Italian_founder_pathogenic_variant,_and_when_found_in_the_homozygous_state_or_in_combination_with_another_pathogenic_MUTYH_variant,_is_known_to_cause_MUTYH-associated_polyposis_(MAP)_(Gismondi_2004,_Eliason_2005,_Di_Gregorio_2006,_Vogt_2009,_Ricci_2017,_de_Leon_2017)._Multiple_in_vivo_and_in_vitro_functional_studies_demonstrate_the_association_of_MUTYH_Glu480del_with_the_defective_removal_of_adenine_bases,_which_is_critical_to_base_excision_repair_(Molatore_2010,_D'Agostino_2010,_Goto_2010,_Ruggieri_2013)._We_consider_this_variant_to_be_pathogenic.||Variant_summary:_The_c.1437_1439delGGA_(p.Glu480del)_in_the_MUTYH_gene_leads_to_an_in-frame_deletion_of_Glu_amino_acid_from_a_non-repeat_region_that_is_located_within_helix-hairpin-helix_DNA-binding_motif._The_variant_is_present_in_the_control_population_dataset_of_gnomAD_at_frequency_of_8.657e-5_(24/_277218_chrs_tested,_including_1_homozygote)._The_variant_of_interest_has_been_reported_in_compound_heterozygosity_or_homozygousity_in_multiple_affected_individuals_who_presented_with_MUTYH-_associated_polyposis._Genotypephenotype_analysis_suggests_that_the_p.Glu480del_variant_is_associated_with_a_severe_phenotype_(Ricci,_2017)._In_vitro_studies_demonstrated_that_the_p.Glu466del_variant_was_dysfunctional_in_complementation_repair_assay_and_had_severely_impaired_glycosylase_activity_(Goto,_2014_and_Komine,_2015)._In_addition,_multiple_reputable_databases/clinical_laboratories_have_classified_the_variant_as_Pathogenic._Taking_together,_the_variant_was_classified_as_Pathogenic.	TCGA_UCEC_221
NM_007194.3:c.470T>C	CHEK2	chr22	29121087	G	7286cf3d-34e0-4c4b-b55d-f9ae8382a71c;bc0717a0-3c12-4a92-88f3-cbd62fc908bf	missense_variant	5&5&4&4	0&2&1&1	rs17879961	Li-Fraumeni syndrome 2&Hereditary cancer-predisposing syndrome&Breast and colorectal cancer, susceptibility to&not provided	5591	20630	Cancer_of_multiple_types,_susceptibility_to|Prostate_cancer,_susceptibility_to|Gastrointestinal_carcinoma|Adrenocortical_carcinoma|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome_2|Breast_and_colorectal_cancer,_susceptibility_to|Colorectal_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|COLON_CANCER,_SUSCEPTIBILITY_TO|not_specified|not_provided	-	.|.|Human_Phenotype_Ontology:HP:0002672,MedGen:C0151544|Human_Phenotype_Ontology:HP:0006744,MeSH:D018268,MedGen:C0206686,Orphanet:ORPHA1501|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836482,OMIM:609265|MedGen:C1858433|MedGen:C1858438|MedGen:C3469522|MedGen:C4016820|MedGen:CN169374|MedGen:CN517202	-	NC_000022.10:g.29121087A>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(7),Pathogenic(7),Uncertain_significance(3)	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:181664|OMIM_Allelic_Variant:604373.0002|UniProtKB_(protein):O96017#VAR_008555	-	CHEK2:11200	SO:0001583|missense_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	17879961	-	OMIM|OMIM|OMIM|OMIM|Ambry_Genetics|Color|True_Health_Diagnostics|GeneKor_MSA|ITMI|Integrated_Genetics/Laboratory_Corporation_of_America|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Pathway_Genomics|Invitae|Counsyl|Mendelics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Center_of_Medical_Genetics_and_Primary_Health_Care|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Division_of_Genomic_Diagnostics,The_Children's_Hospital_of_Philadelphia|GeneDx|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Genetic_Services_Laboratory,_University_of_Chicago|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana|GenomeConnect,_ClinGen	Pathogenic|risk_factor|risk_factor|risk_factor|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|not_provided|Uncertain_significance|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Uncertain_significance|not_provided	2006-11-01|2006-11-01|2006-11-01|2006-11-01|2018-06-20|2014-12-26|2017-11-16|2018-08-01|2013-09-19|2019-04-15|2019-01-02|2014-07-24|2019-01-09|2016-03-15|2018-07-02|2017-06-02|0000-00-00|2015-11-20|2018-05-03|2019-09-30|2019-04-01|2017-02-17|0000-00-00|2016-09-14|2017-06-13|2017-01-01|0000-00-00	2011-11-22|2011-11-22|2011-11-22|2011-11-22|2020-02-26|2016-07-05|2018-03-08|2018-08-08|2014-05-29|2019-09-24|2019-08-05|2014-08-08|2019-03-28|2017-06-22|2018-08-20|2018-06-14|2019-08-31|2016-03-03|2018-05-04|2020-01-06|2019-07-12|2017-08-01|2017-10-31|2018-01-29|2017-07-05|2017-12-08|2019-01-30	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|unknown	SCV000026118|SCV000026119|SCV000026120|SCV000026121|SCV000183804|SCV000292120|SCV000788004|SCV000821722|SCV000084709|SCV000698803|SCV001159433|SCV000189923|SCV000253984|SCV000677722|SCV000839491|SCV000839939|SCV000987254|SCV000266064|SCV000296968|SCV000149927|SCV000575329|SCV000601169|SCV000691835|SCV000806880|SCV000594119|SCV000747421|SCV000986797	Li-Fraumeni_syndrome_2|Colorectal_cancer,_susceptibility_to|Cancer_of_multiple_types,_susceptibility_to|Prostate_cancer,_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|not_specified|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and_colorectal_cancer,_susceptibility_to|Breast_and_colorectal_cancer,_susceptibility_to|not_provided|not_provided|not_provided|not_provided|not_provided|Breast_cancer,_susceptibility_to|Gastrointestinal_carcinoma/Adrenocortical_carcinoma|Breast_cancer,_susceptibility_to/COLON_CANCER,_SUSCEPTIBILITY_TO	||||Significant_disease_association_in_appropriately_sized_case-control_study(ies):Deficient_protein_function_in_appropriate_functional_assay(s):Other_strong_data_supporting_pathogenic_classification|||||Variant_summary:_CHEK2_c.470T>C_(p.Ile157Thr)_results_in_a_non-conservative_amino_acid_change_located_in_the_Forkhead-associated_(FHA)_domain_(IPR000253)_of_the_encoded_protein_sequence._Four_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_0.0042_in_253524_control_chromosomes_in_the_gnomAD_database,_including_11_homozygotes._The_observed_variant_frequency_is_approximately_13.5_fold_of_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_CHEK2_causing_Hereditary_Breast_and_Ovarian_Cancer_phenotype_(0.00031)._In_addition,_this_variant_has_been_reported_in_47/7325_European_American_women_(including_1_homozygote)_who_are_older_than_age_70_and_cancer_free_(in_the_FLOSSIES_database)._These_data_suggest_that_the_variant_is_benign_polymorphism._However,_c.470T>C_has_been_reported_in_the_literature_in_several_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer._In_families_with_this_variant,_transmissions_of_the_variant_allele_and_transmissions_of_the_reference_allele_to_affected_individuals_was_reported_in_addition_to_unaffected_individuals_who_harbored_the_variant_(Allinen_2001,_Dong_2003,_Roeb_2012,_Bak_2014,_Cragun_2014,_Stradella_2018)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease_but_also_suggests_incomplete_segregation_and_incomplete_penetrance_associated_with_this_variant._Co-occurrences_with_other_pathogenic_variants_have_been_reported_in_CHEK2_as_well_as_in_other_genes_associated_with_cancer_(e.g._BRCA2_c.6468_6469delTC_[p.Gln2157fsX18]:_NBN_c.657_661delACAAA_[p.Lys219fsX16]:_BRCA1_c.3700_3704delGTAAA_[p.Val1234fsX8]:_CHEK2_c.444+1G>A:_CHEK2_1100delC_[p.Thr367fsX15]:_CHEK2_c.433C>T_[p.Arg145Trp]),_providing_supporting_evidence_for_a_benign_role,_though_in_some_of_these_cases_the_observed_phenotype_(earlier_onset),_could_also_suggest_an_additive_effect_(Stradella_2018)._Multiple_association_studies_have_produced_conflicting_results,_but_with_an_overall_consensus_for_the_variant_being_associated_with_a_moderate_increased_risk_for_breast_cancer_based_on_a_large_meta-analysis_by_Liu_2012_that_included_a_total_of_fifteen_case-control_studies_(19,621_cases_and_27,001_controls),_showing_a_significant_association_for_unselected_breast_cancer_(OR_	TCGA_UCEC_285;TCGA_UCEC_471
NM_058216.2:c.1026+5_1026+7del	RAD51C	chr17	56809909	-	0ddb51ea-21e4-4977-b151-aa6a148ad1fc	splice_region_variant,intron_variant	-	-	-	-	128201	133658	Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56809910_56809912del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	RAD51C:5889	SO:0001627|intron_variant	1	587781410	-	Ambry_Genetics|Color|Invitae|GeneDx|PreventionGenetics,PreventionGenetics|Laboratoire_de_Biologie_et_Génétique_du_Cancer,Centre_François_Baclesse|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Counsyl	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	2019-10-09|2018-10-17|2018-12-28|2018-11-15|2016-10-17|0000-00-00|2018-05-17|2016-08-06	2020-02-26|2018-11-06|2019-03-28|2019-01-29|2018-01-29|2017-03-06|2018-11-05|2017-06-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown	SCV000184030|SCV000691214|SCV000255311|SCV000150079|SCV000807165|SCV000536678|SCV000886446|SCV000677795	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|not_provided|not_provided|Breast-ovarian_cancer,_familial_3|Breast-ovarian_cancer,_familial_3|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O	Deficient_protein_function_in_appropriate_functional_assay(s):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_falls_in_intron_8_of_the_RAD51C_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_RAD51C_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_present_in_population_databases_(rs587781410,_ExAC_0.004%)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer,_ovarian_cancer,_and_uterine_cancer,_as_well_as_in_an_unaffected_control_individual_(PMID:_22538716,_24139550,_26057125,_27616075,Â¬â€ 29255180)._Segregation_studies_have_not_been_reported_for_this_variant._ClinVar_also_contains_an_entry_for_this_variant_(Variation_ID:_128201)._This_small_deletion_disrupts_the_consensus_donor_splice_site_at_intron_8_of_the_RAD51C_gene._RT-PCR_analysis_using_RNA_extracted_from_the_peripheral_blood_of_carrier_individuals_shows_that_this_variant_may_lead_to_the_skipping_of_exon_8,_resulting_in_a_frameshift_and_the_generation_of_a_premature_stop_codon_in_the_final_exon_of_RAD51C_(PMID:_24139550,_26057125,_28905878)._Although_it_is_not_predicted_to_result_in_nonsense_mediated_decay,_it_does_affect_the_C-terminus_of_the_RAD51C_protein,_which_includes_a_nuclear_localization_signal_that_when_deleted_has_been_shown_to_cause_cellular_mislocalization_(PMID:_12966089)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|This_variant_is_denoted_RAD51C_c.1026+5_1026+7delGTA_or_IVS8+5_IVS8+7delGTA_and_consists_of_a_deletion_of_three_nucleotides_at_the_+5_to_+7_positions_in_intron_8_of_the_RAD51C_gene._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_gtca[delgta]ttat._This_variant_has_been_observed_in_at_least_four_breast/ovarian_cancer_families,_as_well_as_in_one_healthy_control_(Loveday_2012,_Golmard_2013,_Janatova_2015,_Kraus_2017)._In_silico_analyses,_which_include_splice_predictors_and_evolutionary_conservation,_are_inconsistent_in_their_assessment_as_to_whether_or_not_the_variant_is_damaging:_however,_mRNA_studies_showed_this_variant_causes_out-of-frame_skipping_of_exon_8,_resulting_in_a_frameshift_and_truncated_protein_(Golmard_2013,_Davy_2017)._The_disrupted_region_at_the_end_of_the_gene_includes_the_nuclear_localization_signal_(French_2003)._RAD51C_c.1026+5_1026+7delGTA_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._Based_on_currently_available_evidence,_we_consider_RAD51C_c.1026+5_1026+7delGTA_to_be_a_likely_pathogenic_variant.|||The_RAD51C_variant_designated_as_NM_058216.2:c.1026+5_1026+7delGTA_was_previously_classified_as_a_variant_of_uncertain_significance_and_is_now_classified_as_likely_pathogenic._This_variant_is_a_nucleotide_deletion_that_affects_a_consensus_splice_site_in_intron_8_of_the_RAD51C_gene._RNA_studies_of_peripheral_blood_from_individuals_with_the_variant_have_demonstrated_that_the_variant_leads_to_skipping_of_exon_8,_resulting_in_a_frameshift_and_the_generation_of_a_premature_stop_codon_in_the_final_exon_(Golmard_2013,_PMID:241395:_Janatova_2015,_PMID:26057125)._Nonsense-mediated_decay_is_not_expected_to_result_from_this_variant,_but_it_leads_to_a_removal_of_the_nuclear_localization_signal_which_can_cause_cellular_mislocalization_(French_2003,_PMID:12966089)._This_variant_is_not_listed_in_population_databases._It_has_been_reported_in_an_unaffected_control_individual_and_in_individuals_with_breast_cancer,_ovarian_cancer,_and_uterine_cancer_in_multiple_studies_(Loveday_2012,_PMID:22538716:_Golmard_2013,_PMID:2413955:_Janatova_2015,_PMID:26057125:_Kraus_2017,_PMID:27616075)._Bayesian_analysis_integrating_all_of_this_data_(Tavtigian_et_al,_2018,_PMID:29300386)_gives_about_98%_probability_of_pathogenicity_based_largely_on_splice_prediction_and_functional_studies,_which_are_consistent_with_a_classification_of_likely_pathogenic._This_variant_is_predicted_to_alter_RAD51C_function_and_modify_risk_for_cancer._This_analysis_was_performed_in_conjunction_with_the_family_studies_project_as_part_of_the_University_of_Washington_Find_My_Variant_Study.|	TCGA_UCEC_287
NM_032043.2:c.3196del	BRIP1	chr17	59761211	-	861be91b-a756-4ff0-bdda-edee07afad7b	frameshift_variant	-	-	-	-	182367	180926	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59761211del	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	730881645	-	Ambry_Genetics|Invitae|Counsyl|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-01-31|2019-01-02|2017-06-01|2018-10-08|2019-11-21	2020-02-26|2019-03-28|2017-06-22|2019-01-29|2019-12-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline	SCV000276797|SCV000547269|SCV000677806|SCV000210864|SCV000699716	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|Fanconi_anemia,_complementation_group_J/Neoplasm_of_ovary|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome	Other_strong_data_supporting_pathogenic_classification:Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_data_supporting_pathogenic_classification|This_sequence_change_deletes_1_nucleotide_from_exon_20_of_the_BRIP1_mRNA_(c.3196delT),_causing_a_frameshift_at_codon_1066._This_creates_a_premature_translational_stop_signal_in_the_last_exon_of_the_BRIP1_mRNA_(p.Ser1066Hisfs*12)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_result_in_a_truncated_BRIP1_protein_by_eliminating_the_last_173_amino_acids._This_variant_is_present_in_population_databases_(rs730881645,_ExAC_0.05%)._This_variant_has_been_reported_in_an_individual_affected_with_breast_cancer_(PMID:_25186627)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_182367)._This_truncation_affects_the_TopBP1-binding_region_(residues_1130-1153)_of_the_BRIP1_protein._It_is_expected_to_disrupt_the_TopBP1-BRIP1_interaction_that_plays_a_critical_role_on_RPA_chromatin_loading_following_DNA_replication_stress_and_the_subsequent_activation_of_the_replication_checkpoint_in_response_to_DNA_damage_(PMID:_20159562,_21127055)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||This_variant_is_denoted_BRIP1_c.3196delT_at_the_cDNA_level_and_p.Ser1066HisfsX12_(S1066HfsX12)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_TGGA[delT]CATG._This_variant_causes_a_frameshift,_which_changes_a_Serine_to_a_Histidine_at_codon_1066,_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._BRIP1_c.3196delT_has_been_observed_in_at_least_one_individual_with_early-onset_breast_cancer_(Tung_2015)._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation_as_the_last_184_amino_acids_are_lost_and_replaced_with_11_incorrect_amino_acids._The_disrupted_region_at_the_end_of_the_gene_is_located_within_the_TopBP1-binding_region_(Gong_2010)._Based_on_currently_available_evidence,_we_consider_BRIP1_c.3196delT_to_be_likely_pathogenic.|Variant_Summary:_BRIP1_c.3196delT_(p.Ser1066HisfsX12)_results_in_a_premature_termination_codon_in_the_last_exon_of_the_encoded_mRNA,_therefore_it_is_not_expected_to_result_in_nonsense_mediated_decay_(NMD),_but_is_predicted_to_cause_a_truncation_of_the_encoded_protein._No_truncations_downstream_of_this_position_were_classified_as_pathogenic_by_our_laboratory._The_variant_allele_was_found_at_a_frequency_of_2.5e-05_in_282816_control_chromosomes,_exclusively_observed_within_the_African_or_African-American_subpopulation,_at_a_frequency_of_0.00028_(i.e._7/24958_alleles)_in_the_gnomAD_database._In_addition,_this_variant_has_also_been_reported_in_1/2559_African_American_woman_who_was_older_than_age_70_and_cancer_free_(in_the_FLOSSIES_database)._c.3196delT_has_been_reported_in_the_literature_in_individuals_of_African_ancestry,_who_were_affected_with_breast_cancer_(Tung_2014,_Zheng_2018,_Slavin_2019)._However,_large-scale_meta-analyses_found_that_although_BRIP1_mutations_may_confer_risk_for_familial_ovarian_cancer,_but_not_associated_with_increased_risk_for_familial_breast_cancer_(Weber-Lassale_2018,_Suszynska_2018):_therefore_these_reports_do_not_allow_any_conclusions_about_variant_significance._At-least_one_co-occurrence_with_another_pathogenic_variant_has_been_reported_at_our_laboratory_(BRCA1_c.213-11T>G)._Co-occurring_pathogenic_variants_in_different_genes_have_been_reported_in_cancer_cases,_thus_this_is_not_considered_to_weight_as_evidence_supporting_a_benign_impact_of_this_variant._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported_for_this_variant._Though_this_truncation_does_not_affect_any_known_domains,_in_vitro_studies_have_implicated_a_functional_role_for_the_region_downstream_of_this_variant_in_RPA_phosphorylation_in_response_to_replication_stress_(i.e._following_treatment_with_some_DNA_damaging_agents)_(example,_Gong_2010,_Xie_2012),_however_the_contribution_of_these_functional_effects_to_the_disease_pathology_remains_uncertain._Four_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014,_and_all_of_them_classified_the_variant_as_likely_pathogenic._Based_on_two_additional_reports_of_its_presence_in_patients_with_breast_cancer_(Zheng_2018,_Slavin_2019)_since_its_initial_assessment_by_our_laboratory,_until_additional_clinical_and_functional_evidence_becomes_available,_the_variant_was_re-classified_as_likely_pathogenic.	TCGA_UCEC_389
NM_000535.6:c.137G>T	PMS2	chr7	6045549	A	b0f1b9bd-9371-41a8-93b6-71e8dda550f5	missense_variant	4&5&5	3&2&1	rs121434629	Lynch syndrome&Hereditary cancer-predisposing syndrome&not provided	9245	24284	Pituitary_carcinoma|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0011763,MedGen:C0346300,Orphanet:ORPHA300385|MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1838333,OMIM:614337|MedGen:CN169374|MedGen:CN517202	-	NC_000007.13:g.6045549C>A	reviewed_by_expert_panel	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:600259.0012|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:3554|Illumina_Clinical_Services_Laboratory,Illumina:616257|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.137G>T_2|UniProtKB_(protein):P54278#VAR_066838	-	PMS2:5395	SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	121434629	-	OMIM|CSER__CC_NCGL,_University_of_Washington|OMIM|Illumina_Clinical_Services_Laboratory,Illumina|Counsyl|Equipe_Genetique_des_Anomalies_du_Developpement,_Université_de_Bourgogne|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Mendelics|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Mendelics|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Vantari_Genetics|Color|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Invitae|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2013-08-01|2014-06-01|2013-08-01|2016-09-27|2015-05-14|2017-04-19|2018-04-10|2019-05-28|2019-06-21|2015-11-20|2018-03-23|2014-12-11|2018-07-02|2017-11-21|2019-02-12|2016-01-26|2015-07-25|2018-09-28|2015-02-27|2015-12-04|2018-07-16|2018-12-30|2016-03-18|2018-10-31	2016-12-27|2014-08-28|2016-12-27|2019-02-01|2017-06-22|2018-02-06|2018-06-14|2019-10-22|2019-06-21|2016-03-03|2019-03-21|2017-04-19|2018-08-20|2019-04-24|2020-02-26|2016-03-29|2017-10-26|2019-01-29|2018-09-19|2017-08-01|2019-08-05|2019-03-28|2018-08-09|2018-11-14	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|unknown|germline|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown	SCV000030047|SCV000190470|SCV000087493|SCV000469744|SCV000677739|SCV000803859|SCV000840051|SCV001137331|SCV000108292|SCV000266116|SCV000271259|SCV000592923|SCV000838198|SCV000918033|SCV000184825|SCV000267076|SCV000686122|SCV000149566|SCV000227140|SCV000601815|SCV000604885|SCV000253845|SCV000853190|SCV000894431	Turcot_syndrome|Turcot_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_specified|Hereditary_nonpolyposis_colon_cancer|Pituitary_carcinoma|Turcot_syndrome/Hereditary_nonpolyposis_colorectal_cancer_type_4	|||Across_a_selection_of_the_available_literature,_the_PMS2_c.137G>T_(p.Ser46Ile)_missense_variant_has_been_identified_in_at_least_18_heterozygous_or_compound_heterozygous_cases_with_various_cancers_and_three_as-yet_unaffected_heterozygous_family_members_(Agostini_et_al._2005:_Auclair_et_al._2007:_Senter_et_al._2008:_Pastrello_et_al._2011:_Herkert_et_al._2011:_Tomsic_et_al._2013:_Borras_et_al._2013)._The_p.Ser46Ile_variant_was_absent_from_188_control_individuals_and_436_control_chromosomes_but_is_reported_at_a_frequency_of_0.00022_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._The_variant_occurs_at_a_strongly_conserved_residue_in_an_important_functional_domain._Borras_et_al._(2013)_demonstrated_through_in_vitro_expressions_studies_that_the_p.Ser46Ile_variant_had_significantly_reduced_mismatch_repair_activity,_approximately_13%_that_of_wild_type,_while_Drost_et_al._(2013)_showed_that_the_p.Ser46Ile_variant_had_a_mismatch_repair_efficiency_similar_to_that_of_a_known_pathogenic_variant._Based_on_the_evidence,_the_p._Ser46Ile_variant_is_classified_as_likely_pathogenic_for_Lynch_syndrome._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.|||This_c.137G>T_(p.S46I)_variant_in_PMS2_has_been_reported_in_individuals_with_mismatch_repair_deficiency_syndrome,_colon,_endometrial,_colorectal_and_bladder_cancer_(PMID:_21376568,_16144131,_21204794,_22577899,_16619239,_23709753)._In_addition,_functional_studies_have_shown_that_the_c.137G>T_(p.S46I)_variant_significantly_impairs_mismatch_repair_activity_(PMID:_23709753,_24027009)._Therefore,_the_c.137G>T_(p.S46I)_in_the_PMS2_gene_is_classified_as_pathogenic.||>2_MSI_tumours:_deficient_protein_function_inferred_from_2_independent_assays||The_p.Ser46Ile_variant_in_PMS2_has_been_described_as_a_founder_variant_for_lynch_syndrome_in_Caucasians_(Ponti_2015,_Tomsic_2013)._It_has_been_reported_in_the_h_eterozygous_state_in_>15_individuals_with_Lynch_syndrome-associated_cancers,_whe_re_the_tumors_showed_microsatellite_instability_and_loss_of_PMS2_expression_in_s_ome_individuals_(Borras_2013,_Clendenning_2006,_Cock-Rada_2017,_Haraldsdottir_20_13,_Le_2017,_Nakagawa_2004,_Pritchard_2016,_Senter_2008,_Tomsic_2013,_ClinVar:_V_ariation_ID_9245)._This_variant_has_also_been_reported_in_the_biallelic_state_(h_omozygous_or_compound_heterozygous_with_a_second_pathogenic_variant)_in_at_least_9_individuals_with_constitutional_mismatch_repair_deficiency_syndrome_(CMMRD)_a_nd_segregated_with_disease_in_at_least_3_affected_relatives_from_at_least_2_fami_lies_(Auclair_2007,_Borras_2013,_Giunti_2009,_Herkert_2011)._Normal_and_tumor_ti_ssue_from_some_individuals_with_CMMRD_showed_loss_of_expression_of_PMS2_(Agostin_i_2005,_Auclair_2007,_Bodo_2015,_Giunti_2009,_Herkert_2011,_Jackson_2008,_Lavoin_e_2015,_Pastrello_2011,_Stark_2014)._Additionally,_some_relatives_who_were_heter_ozygous_carriers_of_this_variant_were_clinically_unaffected,_suggesting_reduced_penetrance._In_vitro_functional_studies_provide_some_evidence_that_the_p.Ser46Il_e_variant_may_impact_protein_function_(Borras_2013,_Drost_2013,_Nakagawa_2004)._This_variant_has_been_identified_in_35/122744_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSNP_rs1214346_29)._Although_this_variant_has_been_seen_in_the_general_population,_its_frequenc_y_is_low_enough_to_be_consistent_with_the_frequency_and_penetrance_of_PMS2-relat_ed_Lynch_syndrome._Computational_prediction_tools_and_conservation_analysis_sugg_est_that_the_p.Ser46Ile_variant_may_impact_the_protein._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_Lynch_syndrome_in_an_autosoma_l_dominant_manner_and_for_CMMRD_in_an_autosomal_recessive_manner_based_upon_pres_ence_in_multiple_affected_individuals,_segregation_studies,_and_functional_evide_nce._ACMG/AMP_Criteria_applied_(Richards_2015):_PM3_Very_strong:_PS3:_PS4:_PP1:_PP3.|||Variant_summary:_The_PMS2_c.137G>T_(p.Ser46Ile)_variant_involves_the_alteration_of_a_conserved_nucleotide_that_results_in_a_missense_change_within_the_nucleotide_binding_pocket_of_the_ATPase_domain_(Borras_2013)._4/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant_(SNPsandGO_not_captured_due_to_low_reliability_index)._Functional_studies_have_shown_the_variant_to_cause_deficient_MMR_activity_(Borras_2013,_Drost_2013,_van_der_Klift_2016)._This_variant_was_found_in_47/271742_control_chromosomes_(in_gnomAD_and_publication_controls),_however_the_technology_utilized_for_the_gnomAD_dataset_does_not_rule_out_pseudogene_interference_and_thus_this_data_cannot_be_relied_upon._This_variant_has_been_reported_in_several_patients/families_with_Lynch_syndrome-associated_cancers_(in_many_cases_isolated_loss_of_PMS2_was_detected_in_the_tumors)_as_well_as_in_patients_with_constitutional_MMR_deficiency_(CMMR-D)_syndrome_who_also_have_a_second_pathogenic_PMS2_mutation_(in_many_of_these_cases_PMS2_loss_in_normal_tissues_was_documented)_(Clendenning_2006,_Senter_2008,_Herkert_2011,_Tomsic_2013,_Borras_2013,_van_der_Klift_2016)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Other_strong_data_supporting_pathogenic_classification|||This_pathogenic_variant_is_denoted_PMS2_c.137G>T_at_the_cDNA_level,_p.Ser46Ile_(S46I)_at_the_protein_level,_and_results_in_the_change_of_a_Serine_to_an_Isoleucine_(AGT>ATT)._PMS2_Ser46Ile_was_observed_at_an_allele_frequency_of_0.03%_(11/34312)_in_individuals_of_Latino_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_Motif_I_of_the_ATPase_domain_(Guarne_2001)._In-silico_analyses,_including_protein_predictors_and_evolutionary_conservation,_support_a_deleterious_effect._PMS2_Ser46Ile_has_been_published_in_the_literature_as_a_Caucasian_founder_pathogenic_variant_(Senter_2008,_Tomsic_2013,_Ponti_2015)._It_has_been_reported_in_many_individuals_with_Lynch_syndrome-associated_tumors_and_in_many_individuals_with_autosomal_recessive_constitutional_mismatch_repair_deficiency_syndrome_(CMMR-D)_in_the_homozygous_state_or_in_the_compound_heterozygous_state_with_a_second_PMS2_pathogenic_variant_on_the_opposite_chromosome._Tumor_testing_in_many_of_these_individuals_showed_microsatellite_instability_(MSI-H)_and/or_loss_of_PMS2_protein_expression_(Nakagawa_2004,_Agostini_2005,_Clendenning_2006,_Auclair_2007,_Jackson_2008,_Senter_2008,_Van_der_Klift_2010,_Hekert_2011,_Leenen_2011,_Lavoine_2015,_ten_Broeke_2015,_Heath_2016,_Nowak_2016,_van_der_Klift_2016,_Rengifo-Cam_2017)._While_some_functional_studies_have_been_inconclusive,_several_independent_in_vitro_cell-free_complementation_assays_showed_deficient_mismatch_repair_activity_as_well_as_reduced_PMS2_expression_(Nakagawa_2004,_Borras_2013,_Drost_2013)._Based_on_currently_available_evidence,_we_consider_PMS2_Ser46Ile_to_be_a_pathogenic_variant.|||The_PMS2_c.137G>T:p.Ser46Ile_variant_has_been_published_in_the_literature_in_individuals_and_families_with_Lynch_syndrome-associated_cancers_and_constitutional_mismatch_repair-deficiency_(Auclair_2007,_Borras_2013,_Jackson_2008,_Senter_2008,_Tosmic_2013)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_9245)_and_is_found_in_the_Latino_population_with_an_overall_allele_frequency_of_0.03%_(11/34312_alleles)_in_the_Genome_Aggregation_Database._Several_individuals_with_constitutional_mismatch_repair-deficiency_carried_this_variant_in_trans_to_a_second_pathogenic_PMS2_variant_(Auclair_2007,_Jackson_2008,_Senter_2008),_including_another_variant_at_the_same_codon,_p.Ser46Asn,_observed_in_two_affected_individuals_(Jackson_2008,_Senter_2008)._The_serine_at_codon_46_is_highly_conserved_and_both_the_p.Ser46Ile_and_p.Ser46Asn_variants_exhibit_less_than_10%_of_wild-type_activity_in_mismatch_repair_in_vitro_assays_(Borras_2013,_Drost_2013)._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._References:_Auclair_J_et_al._Novel_biallelic_mutations_in_MSH6_and_PMS2_genes:_gene_conversion_as_a_likely_cause_of_PMS2_gene_inactivation._Hum_Mutat._2007_Nov:28(11):1084-90._Borras_E_et_al._Refining_the_role_of_PMS2_in_Lynch_syndrome:_germline_mutational_analysis_improved_by_comprehensive_assessment_of_variants._J_Med_Genet._2013_Aug:50(8):552-63._Drost_M_et_al._Inactivation_of_DNA_mismatch_repair_by_variants_of_uncertain_significance_in_the_PMS2_gene._Hum_Mutat._2013_Nov:34(11):1477-80._Jackson_CC_et_al._Cafe-au-lait_macules_and_pediatric_malignancy_caused_by_biallelic_mutations_in_the_DNA_mismatch_repair_(MMR)_gene_PMS2._Pediatr_Blood_Cancer._2008_Jun:50(6):1268-70._Senter_L_et_al._The_clinical_phenotype_of_Lynch_syndrome_due_to_germ-line_PMS2_mutations._Gastroenterology._2008_Aug:135(2):419-28._Tomsic_J_et_al._Recurrent_and_founder_mutations_in_the_PMS2_gene._Clin_Genet._2013_Mar:83(3):238-43.|This_sequence_change_replaces_serine_with_isoleucine_at_codon_46_of_the_PMS2_protein_(p.Ser46Ile)._The_serine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_serine_and_isoleucine._This_variant_is_present_in_population_databases_(rs121434629,_ExAC_0.02%)._This_variant_has_been_reported_in_trans_with_pathogenic_PMS2_variants_in_multiple_families_with_constitutional_mismatch_repair_deficiency_syndrome_(CMMR-D)_(PMID:_21376568,_16144131,_21204794)._In_separate_analyses,_this_c.137G>T_missense_variant_was_identified_in_more_than_10_probands_with_colon_and/or_endometrial_cancer_(PMID:_22577899,_16619239),_and_has_been_reported_to_segregate_with_colorectal_and_bladder_cancer_in_a_single_family_with_suspected_Lynch_syndrome_(PMID:_23709753)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_9245)._Experimental_studies_have_shown_that_this_missense_change_significantly_impairs_the_mismatch_repair_activity_of_PMS2_(PMID:_23709753,_24027009)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_is_a_missense_variant_in_which_a_G_is_replaced_by_a_T_at_coding_position_137_and_is_predicted_to_change_a_Serine_to_an_Isoleucine_at_codon_46.|	TCGA_UCEC_469
NM_000314.4:c.518G>A	PTEN	chr10	89711900	A	b9ea346c-6313-4b27-ba7d-46b85ecaddf5	missense_variant	-	-	-	-	376032	362911	Neoplasm_of_brain|PTEN_hamartoma_tumor_syndrome|not_provided	-	Human_Phenotype_Ontology:HP:0030692,MeSH:D001932,MedGen:C0006118,SNOMED_CT:126952004|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN517202	-	NC_000010.10:g.89711900G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Nationwide_Children's_Hospital:PTENv2017-23	-	PTEN:5728	SO:0001623|5_prime_UTR_variant	27	121913294	-	Database_of_Curated_Mutations_(DoCM)|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Herman_Laboratory,Nationwide_Children's_Hospital|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2015-07-14|2017-12-27|0000-00-00|2017-03-01|2018-02-27|2016-10-20	2016-07-18|2019-01-29|2017-10-31|2017-05-24|2018-08-29|2019-03-21	no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	somatic|germline|unknown|maternal|germline|germline	SCV000504815|SCV000566605|SCV000692014|SCV000579279|SCV000645595|SCV000711962	Neoplasm_of_brain|not_provided|not_provided|PTEN_hamartoma_tumor_syndrome|PTEN_hamartoma_tumor_syndrome|PTEN_hamartoma_tumor_syndrome	|This_pathogenic_variant_is_denoted_PTEN_c.518G>A_at_the_cDNA_level,_p.Arg173His_(R173H)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Histidine_(CGC>CAC)._This_variant_has_been_observed_in_multiple_individuals_with_findings_consistent_with_PTEN_Hamartoma_Tumor_syndrome_(Lachlan_2007,_Varga_2009,_McBride_2010,_Bubien_2013,_Hansen-Kiss_2017)._Functional_studies_have_shown_that_this_variant_results_in_reduced_phosphatase_activity_(Han_2000,_Rodriguez-Escudero_2011)._PTEN_Arg173His_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_Phosphatase_domain_(Wang_2008)._In-silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_the_current_evidence,_we_consider_PTEN_Arg173His_to_be_pathogenic.|||This_sequence_change_replaces_arginine_with_histidine_at_codon_173_of_the_PTEN_protein_(p.Arg173His)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_histidine._This_variant_is_present_in_population_databases_(rs121913294,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_and_families_affected_with_PTEN_hamartoma_tumor_syndrome_(PMID:_17526800,_19265751,_20533527,_23335809,_Invitae_database)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_376032)._Experimental_studies_in_E._coli_have_shown_that_this_missense_change_abolishes_the_phosphatase_activity_of_the_PTEN_protein_(PMID:_10866302)._A_different_missense_substitution_at_this_codon_(p.Arg173Cys)_has_been_determined_to_be_pathogenic_(PMID:_10866302,_17526800,_25669429,_28475857)._This_suggests_that_the_arginine_residue_is_critical_for_PTEN_protein_function_and_that_other_missense_substitutions_at_this_position_may_also_be_pathogenic._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Arg173His_variant_has_been_reported_in_4_individuals_with_clinical_feature_s_of_Cowden_syndrome_(Lachlan_2007,_Mcbride_2010,_Bubien_2013)_and_segregated_wi_th_disease_in_2_affected_relatives_from_2_different_families_(Lachlan_2007,_Varg_a_2004)._In_addition,_it_segregated_with_macrocephaly_in_1_relative_from_a_third_family_(McBride_2010)._This_variant_has_been_identified_in_1/10324_African_chro_mosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.or_g:_dbSNP_rs121913294)._This_variant_has_been_observed_as_a_somatic_mutation_in_t_umors,_including_glioblastoma_(Duerr_1998)_and_colorectal_cancer_(Day_2013)._The_p.Arg173His_variant_is_associated_with_decreased_protein_activity_in_vitro_(Han_2000,_Rodriguez-Escudero_2011)._However,_these_types_of_assays_may_not_accurate_ly_represent_biological_function._In_summary,_although_additional_studies_are_re_quired_to_fully_establish_its_clinical_significance,_the_p.Arg173His_variant_is_likely_pathogenic_in_an_autosomal_dominant_manner.	TCGA_UCEC_478
